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A B S T R A C T
Background
Hepatic encephalopathy is a common complication of cirrhosis which results in poor brain functioning. The spectrum of changes
associated with hepatic encephalopathy ranges from the clinically ’indiscernible’ or minimal hepatic encephalopathy to the clinically
’obvious’ or overt hepatic encephalopathy. Flumazenil is a synthetic benzodiazepine antagonist with high affinity for the central
benzodiazepine recognition site. Flumazenil may benefit people with hepatic encephalopathy through an indirect negative allosteric
modulatory effect on gamma-aminobutyric acid receptor function. The previous version of this review, which included 13 randomised
clinical trials, found no effect of flumazenil on all-cause mortality, based on an analysis of 10 randomised clinical trials, but found a
beneficial effect on hepatic encephalopathy, based on an analysis of eight randomised clinical trials.
Objectives
To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic
encephalopathy.
Search methods
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation
Index Expanded, and LILACS; meeting and conference proceedings; and bibliographies in May 2017.
Selection criteria
We included randomised clinical trials regardless of publication status, blinding, or language in the analyses of benefits and harms, and
observational studies in the assessment of harms.
Data collection and analysis
Two review authors extracted data independently. We undertook meta-analyses and presented results using risk ratios (RR) with 95%
confidence intervals (CI) and I2 values as a marker of heterogeneity.We assessed bias control using the Cochrane Hepato-Biliary Group
domains; determined the quality of the evidence using GRADE; evaluated the risk of small-study effects in regression analyses; and
conducted trial sequential, subgroup, and sensitivity analyses.
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Main results
We identified 14 eligible randomised clinical trials with 867 participants, the majority of whom had an acute episode of overt hepatic
encephalopathy. In addition, we identified one ongoing randomised clinical trial. We were unable to gather outcome data from 2
randomised clinical trials with 25 participants. Thus, our analyses include 842 participants from 12 randomised clinical trials comparing
flumazenil versus placebo. We classified one randomised clinical trial at low risk of bias in the overall assessment and the remaining
randomised clinical trials at high risk of bias. The duration of follow-up ranged from a few minutes to two weeks, but it was less than
one day in the majority of the trials.
In total, 32/433 (7.4%) participants allocated to flumazenil versus 38/409 (9.3%) participants allocated to placebo died (RR 0.75, 95%
CI 0.48 to 1.16; 11 randomised clinical trials; low quality evidence). The Trial Sequential Analysis and the one randomised clinical
trial assessed as low risk of bias (RR 0.76, 95% CI 0.37 to 1.53) found no beneficial or harmful effects of flumazenil on all-cause
mortality. The methods used to evaluate hepatic encephalopathy included several different clinical scales, electrophysiological variables,
and psychometric tests. Flumazenil was associated with a beneficial effect on hepatic encephalopathy when including all randomised
clinical trials (RR 0.75, 95% CI 0.71 to 0.80; 824 participants; 9 randomised clinical trials; low quality evidence), or just the trial at low
risk of bias (RR 0.78, 95% CI 0.72 to 0.84; 527 participants). The Trial Sequential Analysis supported a beneficial effect of flumazenil
on hepatic encephalopathy. The randomised clinical trials included little information about causes of death and little information on
non-fatal serious adverse events.
Authors’ conclusions
We found lowquality evidence suggesting a short-termbeneficial effect of flumazenil on hepatic encephalopathy in people with cirrhosis,
but no evidence of an effect on all-cause mortality. Additional evidence from large, high quality randomised clinical trials is needed to
evaluate the potential benefits and harms of flumazenil in people with cirrhosis and hepatic encephalopathy.
P L A I N L A N G U A G E S U M M A R Y
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Background
What is hepatic encephalopathy?
Cirrhosis is a chronic disorder of the liver. People with cirrhosis may develop hepatic encephalopathy, a condition which results in poor
brain functioning. In some people, there are obvious clinical features of disturbed brain functioning (overt hepatic encephalopathy);
these changes may be short-lived or persist for long periods of time. In other people, there are no obvious clinical changes but some
aspects of brain function, such as attention and the ability to perform complex tasks are impaired when tested (minimal hepatic
encephalopathy). The reason people develop hepatic encephalopathy is complex but changes in brain neurotransmitters, which are
the chemical messengers which allow nerve cells to communicate with one another, may play a role. The neurotransmitter gamma
aminobutyric acid (GABA) is responsible for slowing or inhibiting brain activity and is thought to play a particularly important role.
What is flumazenil?
Flumazenil is a medicine that acts on one of the GABA receptors in the brain to modify its effects on these specialised cells and so may
benefit people with hepatic encephalopathy. It has to be given into a vein (intravenous) and its effects do not last for more than a few
hours.
Review question
We investigated the use of flumazenil for the treatment of hepatic encephalopathy in people with cirrhosis by reviewing clinical trials
in which people were randomly allocated to treatment with flumazenil or an inactive dummy/placebo or no specific intervention.
Search date
We searched medical databases and conducted manual searches in May 2017.
Study funding sources
Five of the included randomised clinical trials received support from pharmaceutical companies.
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Study characteristics
We included 14 randomised clinical trials with 867 participants. All randomised clinical trials compared intravenous infusion of
flumazenil versus an inactive placebo (dummy infusion, e.g. a salt solution). The duration of treatment ranged from 10 minutes to 72
hours. Ten randomised clinical trials included participants with overt hepatic encephalopathy; three included participants with minimal
hepatic encephalopathy; and one randomised clinical trial included participants with overt or minimal hepatic encephalopathy.
Key results
The analyses showed no effect of flumazenil on all-cause mortality (deaths of any cause) compared with placebo. People who received
flumazenil were more likely to recover from their hepatic encephalopathy than people given a placebo. We found little information
about serious side effects.
Quality of the evidence
Overall, the evidence for the effect of flumazenil on hepatic encephalopathy was of low quality; only one randomised clinical trial
included had a low risk of bias.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Flumazenil versus placebo for people with cirrhosis and hepatic encephalopathy
Patient or population: people with hepat ic encephalopathy
Setting: hospital
Intervention: f lumazenil
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with flumazenil
All- cause mortality
f ollow-up: range 1 day
to 2 weeks
Study populat ion RR 0.75
(0.48 to 1.16)
842
(11 RCTs)
⊕⊕©©
Low 1,2
The only RCT with low
risk of bias found no ef -
fect of f lumazenil on all-
cause mortality (RR 0.
76, 95% CI 0.37 to 1.53)
. The Trial Sequent ial
Analysis found insuf f i-
cient evidence to sup-
port or refute an inter-
vent ion benef it / harm
93 per 1000 70 per 1000
(45 to 108)
Hepatic encephalopa-
thy
Study populat ion RR 0.75
(0.71 to 0.80)
824
(9 RCTs)
⊕⊕©©
Low 1,2
The only RCT with a
low risk of bias reported
a benef icial ef fect of
f lumazenil on hepat ic
encephalopathy (RR 0.
78, 95% CI 0.72 to
0.84; Barbaro 1998)
. The Trial Sequen-
t ial Analysis found that
f lumazenil was asso-
ciated with a benef i-
cial ef fect on hepat ic
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encephalopathy (Figure
1). The methods used
to assess this out-
come varied consider-
ably (Table 1) and the
durat ion of follow-up
was very short in the
majority of RCTs.
933 per 1000 700 per 1000
(662 to 746)
Serious adverse events See comment See comment Not est imable 842
(11 RCTs)
⊕⊕©©
Low 1,2
All-cause mortality was
the only serious ad-
verse event reported
for both the interven-
t ion and control group
(Table 6). The narrat ive
text in 4 RCTs described
that causes of death in-
cluded liver failure, pro-
gressive liver disease,
and infect ions
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT: randomised clinical trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to risk of bias: only one RCT had a low risk of bias.
2 Downgraded due to imprecision: wide conf idence intervals.
5
F
lu
m
a
z
e
n
il
v
e
rsu
s
p
la
c
e
b
o
o
r
n
o
in
te
r
v
e
n
tio
n
fo
r
p
e
o
p
le
w
ith
c
irrh
o
sis
a
n
d
h
e
p
a
tic
e
n
c
e
p
h
a
lo
p
a
th
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Figure 1. Trial Sequential Analysis of randomised clinical trials evaluating flumazenil versus placebo for
people with hepatic encephalopathy. The outcome is all-cause mortality. The original meta-analysis included
11 randomised clinical trials with 842 participants. The Trial Sequential Analysis ignored three randomised
clinical trials due to insufficient information size (Cadranel 1995; Gyr 1996; Zhu 1998). The analysis was made
with alpha 3%, power 90%, relative risk reduction 20%, assumed control risk 10%, and diversity 10%. The blue
line (Z-curve) corresponds to the cumulative meta-analysis, the black horizontal line is the conventional
boundary (3% level of significance), and the inward sloping green line is the Trial Sequential Monitoring
Boundary. Futility boundaries are ignored because the information is insufficient. The analysis found no
evidence to support or refute a beneficial or harmful effect of flumazenil on mortality.
B A C K G R O U N D
Description of the condition
Hepatic encephalopathy is the term used to describe the spectrum
of neuropsychiatric changes that canoccur in peoplewith cirrhosis.
The joint guideline from the European Association for the Study
of the Liver (EASL) and the American Association for the Study
of Liver Diseases (AASLD) defines hepatic encephalopathy as
brain dysfunction associated with liver insufficiency or portal sys-
temic shunting (EASL/AASLD guideline 2014a; EASL/AASLD
guideline 2014b).
Clinically apparent orovert hepatic encephalopathy manifests as
a neuropsychiatric syndrome encompassing a wide spectrum of
mental and motor disorders (Weissenborn 1998; Ferenci 2002).
Events such as gastrointestinal bleeding, infection, and alcohol
misuse can trigger this so-called acute or episodic hepatic en-
cephalopathy. Fifty per cent of instances occur with no obvi-
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ous precipitating cause. Episodes may recur. Between episodes,
people may return to their baseline neuropsychiatric status or
retain a degree of impairment (Bajaj 2010). Less frequently, peo-
ple present with persistent neuropsychiatric abnormalities, which
are always present to some degree, but which may vary in serious-
ness. The clinical features of overt hepatic encephalopathy ranges
from subtle alterations in personality, intellectual capacity and
cognitive function to more profound alterations in motor func-
tion and consciousness leading to deep coma (Weissenborn 1998).
Other abnormalities include impaired psychometric performance
(Schomerus 1998; Randolph 2009), disturbed neurophysiolog-
ical function (Parsons-Smith 1957; Chu 1997), altered cerebral
neurochemical/neurotransmitter homeostasis (Taylor-Robinson
1994), reductions in global and regional cerebral blood flow and
metabolism (O’Carroll 1991), and changes in cerebral fluid home-
ostasis (Haussinger 2000). In general, the degree of impairment in
these parameters increases as the clinical condition worsens.Mini-
mal hepatic encephalopathy (in the older literature ’subclinical’ or
’latent’) refers to people with cirrhosis who are ’clinically normal,’
but who show abnormalities in neuropsychometric or neurophys-
iological performance (Ferenci 2002). Hepatic encephalopathy,
whether minimal or overt, is associated with impairment in the
performance of complex tasks, such as driving (Schomerus 1981;
Bajaj 2009; Kircheis 2009), and a detrimental effect on health-re-
lated quality of life (Groeneweg 1998), safety (Roman 2011), neu-
rocognitive function post-transplantation (Sotil 2009), and sur-
vival (Bustamante 1999; D’Amico 2006; Stewart 2007). About
42% of people with cirrhosis are alive one year after their first
episode of hepatic encephalopathy but only 23% are alive after
three years (Bustamante 1999). Thus, more than 50% die within
one year and more than 75% die within three years. Hepatic en-
cephalopathy also poses a substantial burden for the carers of af-
fected people (Bajaj 2011) and on healthcare systems (Poordad
2007; Stepanova 2012).
Prevalence of hepatic encephalopathy
The prevalence of hepatic encephalopathy varies. About 10% to
14% of people with cirrhosis have overt hepatic encephalopathy at
the time they are first diagnosed as having liver disease (Saunders
1981). In people with decompensated cirrhosis the prevalence of
overt hepatic encephalopathy is around 20% (D’Amico 1986; de
Jongh 1992; Zipprich 2012). The cumulated incidence of overt
hepatic encephalopathy is as high as 40% (Randolph 2009; Bajaj
2011). The prevalence of minimal hepatic encephalopathy varies
but may be as high as 50% (Lauridsen 2011).
Diagnosing hepatic encephalopathy
There is no gold standard for the diagnosis of hepatic encephalopa-
thy. A detailed neuropsychiatric history and examination is impor-
tant to identify suggestive abnormalities while eliminating other
potential causes of similar cerebral changes (Montagnese 2004).
The West Haven or Conn criteria are commonly used to assess
and grade themental state (Conn 1977), while the GlasgowComa
Scale is used to grade the level of consciousness (Teasdale 1974).
People with hepatic encephalopathy show impairment on a range
of psychometric tests. People with minimal hepatic encephalopa-
thy show deficits in attention, visuo-spatial abilities, fine motor
skills, and memory while other cognitive functions are relatively
well preserved. People with overt hepatic encephalopathy show
additional disturbances in psychomotor speed, executive function,
and concentration. The Psychometric Hepatic Encephalopathy
Score, which employs five paper and pencil tests to assess atten-
tion, visual perception and visuo-constructive abilities is widely
used in the assessment of psychometric change in people with cir-
rhosis (Schomerus 1998; Weissenborn 2001). People with hep-
atic encephalopathy may have a number of neurophysiological
abnormalities (Guérit 2009). The electroencephalogram, which
primarily reflects cortical neuronal activity, may show progressive
slowing of background activity and abnormal wave morphology.
The brain responses, or evoked potentials, to stimuli such as light
and sounds may show abnormal slowing or abnormal wave forms.
Other potential diagnostic techniques include the Critical Flicker
Fusion Frequency (Kircheis 2002), and the Inhibitory Control
Test (Bajaj 2008). Blood ammonia concentrations are not rou-
tinely measured to diagnose hepatic encephalopathy but they are
sometimes monitored in clinical trials.
Description of the intervention
The pathogenesis of hepatic encephalopathy is complex and in-
completely understood. It is associated with a general depression
in cerebral function and a shift in balance between inhibitory
and excitatory neurotransmission favouring inhibition. Gamma
aminobutyric acid (GABA) is the major inhibitory neurotrans-
mitter in the brain; it binds to a specific receptor; the GABA-A-
complex, which also has neurosteroid and benzodiazepine modu-
latory sites (Butterworth 2016). People with hepatic encephalopa-
thy have been shown to have increased ’GABA tone’. Use of a
benzodiazepine receptor antagonist may counteract the increased
tone and benefit people with hepatic encephalopathy (Ahboucha
2008).
Flumazenil competitively inhibits the activity at the benzodi-
azepine recognition site on the GABA-A receptor complex, but
lacks major intrinsic pharmacological or behavioural activity
(Whitwam 1995). Flumazenil is used to treat benzodiazepine over-
dose and in the reversal of anaesthesia. Following intravenous ad-
ministration, flumazenil distributes extensively in the extravascu-
lar space with an initial distribution half-life of 4 to 11 minutes
and a terminal half-life of 40 to 80 minutes. Maximum plasma
concentrations are reached at around 50 minutes. Flumazenil is
completely metabolised primarily by hepatic metabolism and has
a relatively high hepatic extraction ratio (Amrein 1990). In people
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with moderate liver dysfunction, the mean total clearance is de-
creased to 40% to 60%. In people with severe liver dysfunction,
clearance is decreased to 25%. This results in a prolongation of
the half-life from 50 minutes in healthy volunteers to 1.3 hours in
people with moderate hepatic impairment and 2.4 hours in peo-
ple with severe hepatic dysfunction (Amrein 1990). Nevertheless,
even in people with severe liver disease, its duration of action re-
mains relatively short.
How the intervention might work
Glutamate dehydrogenase synthesises GABA from glutamate in
presynaptic nerves.GABAbinds to a specific receptor, which is em-
bedded in the postsynaptic neural membrane. This receptor is part
of a larger GABA-A receptor complex, which also has binding sites
for benzodiazepines, barbiturates, and neurosteroids. The binding
of any of these ligands opens a chloride channel; the influx of chlo-
ride ions results in hyperpolarisation of the postsynaptic mem-
brane and neuro-inhibition. Neurosteroids are synthesised in the
brain, primarily in astrocytes, and mediates an increased GABA-
A tone, which is associated with hepatic encephalopathy. Neuros-
teroid synthesis is mediated via activation of translocator protein,
a mitochondrial neuroglial cholesterol-transporter protein previ-
ously (Butterworth 2016). Translocator protein sites (previously
known as ’peripheral-type’ or mitochondrial) benzodiazepine re-
ceptors. Neurosteroids such as 3α-5α-tetrahydroprogesterone (al-
lopregnanolone) are potent, endogenous, positive allosteric mod-
ulators of both the GABA and benzodiazepine sites on the GABA-
A receptor complex. Autopsy and imaging studies show consistent
upregulation of translocator protein sites in people with hepatic
encephalopathy. This upregulation is most likely mediated by am-
monia and manganese (Ahboucha 2008), both of which accumu-
late as a result of hepatocellular failure and portal-systemic shunt-
ing of blood. In addition, cerebrospinal fluid and autopsied brains
of people with hepatic encephalopathy have increased concentra-
tions of agonist ligands such as diazepam-binding inhibitor and
octadecaneuropeptide, which modulate the function of transloca-
tor protein sites (Córdoba 2002). People who die from hepatic en-
cephalopathy have increased cerebral concentrations of allopreg-
nanolone, which modulates components of the GABA-A recep-
tors. The neurosteroidsmay also act synergistically with other neu-
rotoxins such as ammonia and benzodiazepine-like compounds to
further modulate GABA-A receptor function. The net effect is an
increase in GABA-A tone and neural inhibition. Involvement of
the GABA system in the pathogenesis of hepatic encephalopathy
is consistent with the increased sensitivity to benzodiazepines ob-
served in these patients (Batki 1987).
Flumazenil is a selective, synthetic benzodiazepine antagonist with
high affinity for the benzodiazepine recognition site but is itself
devoid of intrinsic activity. This compound functions as an antag-
onist of positive and negative modulators acting at benzodiazepine
recognition sites located in the GABA-A receptor (Vicini 1987).
Flumazenil may exert an indirect negative allosteric modulatory
effect on GABA-A receptor function by reducing the facilitatory
action of the central benzodiazepine receptor on GABA-related
opening of the chloride ion-channel and in turn the excessive in-
hibitory effect.
Why it is important to do this review
The resource utilisation associated with the management of peo-
ple with hepatic encephalopathy continues to escalate (Poordad
2007; Stepanova 2012). The costs of treatment and rehabilitation
are increasing year on year (Neff 2010). The Identification of ef-
fective interventions which will facilitate the management of peo-
ple with hepatic encephalopathy is clearly important. A number
of randomised clinical trials have assessed the effects of flumazenil
in people with cirrhosis and hepatic encephalopathy (Klotz 1989;
Hermant 1991; Cadranel 1995;Gooday 1995;Gyr 1996; Amodio
1997; Barbaro 1998; Giger-Mateeva 1999; Dursun 2003). The
numbers of the randomised clinical trials and of the included
participants is small and several studies used a cross-over design,
which hampers the analyses of clinical outcomes such as mortality
and morbidity. A meta-analysis undertaken in 2002 found that
use of flumazenil may be associated with clinical and electroen-
cephalographic improvement in people with cirrhosis and hepatic
encephalopathy (Goulenok 2002). The previous versions of this
review included 13 randomised clinical trials (Als-Nielsen 2001;
Als-Nielsen 2004) and found no beneficial effect of flumazenil on
all-cause mortality, but a potential beneficial effect on manifes-
tations of hepatic encephalopathy. We have updated this review
based on current recommendations (Gluud 2017).
O B J E C T I V E S
To evaluate the beneficial and harmful effects of flumazenil versus
placebo or no intervention for people with cirrhosis and hepatic
encephalopathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised clinical trials regardless of their publi-
cation status, language, or blinding in our primary analyses. If,
during the selection of trials, we identified observational studies
(i.e. quasi-randomised studies, cohort studies, or patient reports)
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that reported adverse events caused by, or associated with, the in-
terventions in our review, we included these studies for a review of
the adverse events. We did not specifically search for observational
studies for inclusion in this review, which is a known limitation.
Types of participants
Randomised clinical trials evaluating participants with cirrhosis
andhepatic encephalopathy, irrespective of the aetiology and sever-
ity of the underlying liver disease. Included participants could have
overt or minimal hepatic encephalopathy. If we identified trials
including subsets of relevant participants with cirrhosis as well as
participants without cirrhosis, we planned to exclude these trials
in sensitivity analyses.
Types of interventions
Flumazenil at any dose, duration, ormode of administration versus
placebo or no intervention.
Types of outcome measures
We assessed all outcomes at the maximum duration of follow-up.
Primary outcomes
• All cause-mortality.
• Hepatic encephalopathy (number of participants without
improved manifestations).
• Serious adverse events defined as any untoward medical
occurrence that resulted in death, was life-threatening, required
hospitalisation, led to prolongation of the existing
hospitalisation, or resulted in persistent or significant disability
(ICH-GCP 1997). We analysed serious adverse events as a
composite outcome (Gluud 2017).
Secondary outcomes
• Non-serious adverse events defined as any adverse event
that did not fulfil the criteria for a serious adverse event.
• Health-related quality of life.
Exploratory outcomes
• Number Connection Test results.
Search methods for identification of studies
The last search update was May 2017.
Electronic searches
We searchedTheCochraneHepato-BiliaryGroupControlledTri-
als Register (Gluud 2017), Cochrane Central Register of Con-
trolled Trials (CENTRAL; 2017, Issue 2) in the Cochrane Library
(searched May 2017), MEDLINE Ovid (1946 to May 2017),
Embase Ovid (1974 to May 2017), Science Citation Index Ex-
panded (Web of Science; 1900 to May 2017) (Royle 2003), and
LILACS (Bireme; 1982 toMay 2017) using the strategy described
in Appendix 1. We did not have access to Chinese or Japanese
databases. We plan to search both Chinese and Japanese databases
in future updates, should they become available to us via the
Cochrane Hepato-Biliary Group.
Searching other resources
We searched the reference lists of papers identified in the electronic
searches and wrote to authors of the identified clinical trials and
relevant pharmaceutical companies. We searched the conference
proceedings of the European Association for the Study of the Liver
(EASL), the United European Gastroenterology Week (UEGW),
the American Gastroenterological Association (AGA), the Amer-
ican Association for the Study of Liver Diseases (AASLD), the
International Society for Hepatic Encephalopathy and Nitrogen
metabolism (ISHEN), the World Health Organization (WHO)
online trial meta-register (apps.who.int/trialsearch/), and Google
Scholar using the search terms cirrhosis AND flumazenil.
Data collection and analysis
Selection of studies
Three review authors (ETG, MYM, and LLG), working indepen-
dently, read the updated electronic searches, performed additional
handsearches, and listed potentially eligible trials. All authors read
the potentially eligible trials and participated in the final selection
of those to be included in the analyses. For trials reported in more
than one publication, we selected the paper reporting the longest
duration of follow-up as the primary reference. We listed details
of all included trials in a ’Characteristics of included studies’ table
and listed all excluded studies with the reason for their exclusion
in a ’Characteristics of excluded studies table’.
Data extraction and management
All review authors participated in data extraction and at least two
review authors independently evaluated each randomised clinical
trial. We resolved disagreements through discussion and sought
key unpublished information thatwasmissing frompublished trial
reports, through correspondence with the primary investigators of
included randomised clinical trials.
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Where wewere not able to gather sufficient data (number of events
and participants) from the text and tables of the included reports
of randomised clinical trials or from correspondence with investi-
gators we attempted to extrapolate data , where possible from any
contained graphical material.
We gathered data on the following:
• Trials: design (cross-over or parallel), setting (number of
clinical sites), country of origin, inclusion period;
• Participants: mean age, proportion of men, type of hepatic
encephalopathy, proportion with cirrhosis, proportion with
alcoholic liver disease, proportion with viral hepatitis;
• Interventions: type, dose, duration of therapy, mode of
administration;
• Outcomes: outcomes assessed, criteria used in the
assessment of hepatic encephalopathy.
Assessment of risk of bias in included studies
We assessed bias control using the domains described in the
Cochrane Hepato-Biliary Group Module (Gluud 2017) and clas-
sified the risk of bias for separate domains as high, unclear, or low.
We also included an overall assessment of bias control as described
below:
Allocation sequence generation
• Low risk of bias: sequence generation achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, or throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: not described.
• High risk of bias: sequence generation method was not
random.
Allocation concealment
• Low risk of bias: used a central and independent
randomisation unit or similar adequate method (e.g. serially
numbered opaque sealed envelopes) to ensure that the allocation
sequence was unknown to the investigators (Hrobjartsson 2001;
Savovic 2012a; Savovic 2012b).
• Unclear risk of bias: allocation not described.
• High risk of bias: allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: blinding of participants and personnel
performed adequately using a placebo. We defined lack of
blinding as not likely to affect the evaluation of mortality.
• Unclear risk of bias: insufficient information to assess
blinding.
• High risk of bias: no blinding or incomplete blinding.
Blinding of outcome assessors
• Low risk of bias: blinding of outcome assessors performed
adequately using a placebo. We defined lack of blinding as not
likely to affect the evaluation of mortality (Hrobjartsson 2001;
Savovic 2012a; Savovic 2012b).
• Unclear risk of bias: there was insufficient information to
blinding.
• High risk of bias: no blinding or incomplete blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The investigators
used sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses to handle missing
data.
• Unclear risk of bias: there was insufficient information to
assess missing data.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically relevant
outcomes (all-cause mortality, hepatic encephalopathy, and
serious adverse events). If we had access to the original trial
protocol, the outcomes selected should have been those
described in the protocol. If we obtained information from a trial
registry (such as www.clinicaltrials.gov), we only used that
information if the investigators registered the trial before
inclusion of the first participant.
• Unclear risk of bias: predefined relevant outcomes were not
reported fully or the reporting was unclear.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appeared free of industry
sponsorship or other type of for-profit support.
• Unclear risk of bias: no information on clinical trial support
or sponsorship.
• High risk of bias: the trial was sponsored by industry or
received other support (such as provision of study drugs).
Other bias
• Low risk of bias: the trial appeared free of other biases
including: medicinal dosing problems or follow-up (as defined
below).
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• Unclear risk of bias: the trial may or may not have been free
of other domains that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an
inappropriate dose) or follow-up (e.g. the trial included different
follow-up schedules for participants in the allocation groups).
Overall bias assessment
• Low risk of bias: all domains were low risk of bias using the
definitions described above.
• High risk of bias: one or more of the bias domains were of
unclear or high risk of bias.
Measures of treatment effect
We analysed dichotomous data using risk ratios (RR) and contin-
uous data using mean differences (MD), both with 95% confi-
dence intervals (CI).
Unit of analysis issues
Due to the fluctuating nature of hepatic encephalopathy and the
nature of our primary outcomes, we included randomised clinical
trials using a parallel-arm design and the first treatment period
from cross-over trials.
Dealing with missing data
We extracted data on all participants randomised to allow inten-
tion-to-treat analyses. We planned to undertake analyses to evalu-
ate the influence of missing data (Higgins 2008) including worst-
case scenario analysis, and extreme worst-case and best-case sce-
nario analyses (Gluud 2017). However, we did not identify ran-
domised clinical trials with missing outcome data.
Assessment of heterogeneity
We assessed heterogeneity through visual inspection of the forest
plots and expressed heterogeneity as I2 values using the following
thresholds: 0% to 40% (unimportant), 40% to 60% (moderate),
60% to 80% (substantial), and greater than 80% (considerable).
We included the information in our ’Summary of findings’ tables.
Assessment of reporting biases
For meta-analyses with at least 10 randomised clinical trials (meta-
analysis evaluating all-cause mortality), we planned to prepare
funnel plots and regression analyses of funnel plot asymmetry
(Harbord 2006). However, our analyses included fewer than 10
randomised clinical trials.
Data synthesis
We performed the analyses using Review Manager 5 (RevMan
2014), STATA (Stata 14), and Trial Sequential Analysis (TSA
2011).
Meta-analysis
We performed random-effects and fixed-effect meta-analyses. The
estimates of the random-effects andfixed-effectmeta-analyseswere
similar for all analyses. Therefore, we assumed that any small-
study effects had little effect on the intervention effect estimate.
For random-effects models, precision decreased with increasing
heterogeneity and CIs widened correspondingly. Accordingly, the
random-effects model provided themost conservative (and amore
correct) estimate of the intervention effect. Accordingly, we report
the results of our analyses based on random-effects meta-analyses.
Trial Sequential Analysis
We performed Trial Sequential Analysis to evaluate the risk of
errors and to evaluate futility (Wetterslev 2008; Thorlund 2011;
Wetterslev 2017). We defined the required information size as the
number of participants needed to detect or reject an intervention
effect. We set alpha to 3% and power to 90% in all analyses. We
used the model-based diversity and repeated all analyses with a
diversity increased by 10%. Due to the lack of randomised clinical
trials assessed at low risk of bias, we were only able to conduct the
analyses with inclusion of all randomised clinical trials (regardless
of bias control).
All-cause mortality: based on one large randomised clinical
trial evaluating flumazenil (Barbaro 1998), and cohort studies
evaluating the prognosis of people with hepatic encephalopa-
thy (EASL/AASLD guideline 2014a; EASL/AASLD guideline
2014b), as well as the results of our meta-analysis, we set the rel-
ative risk reduction to 10%, the control group risk to 20%, and
increased diversity to 10%.
Hepatic encephalopathy: based on the Cochrane Hepato-Biliary
Group recommendations, we conducted the analysiswith a relative
risk reduction of 20% (corresponding to the upper 95% CI) and
reduced the control group risk from the observed 93% to 60%
(set lower than the observed control group risk).
Serious adverse events: we were only able to identify serious ad-
verse events that were fatal. Accordingly, our analysis of all-cause
mortality and serious adverse events included the same numbers.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses to investigate heterogeneity in
randomised clinical trials based on the:
• Type of hepatic encephalopathy;
• Inclusion of participants with cirrhosis or acute liver failure
• The trial design;
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• Duration of follow-up.
Only one randomised clinical trial had a low risk of bias in the
overall assessment.
Sensitivity analysis
We planned to perform worst-case scenario analyses, but none of
the trials reported missing outcome data.
’Summary of findings’ table
We used GRADEpro (GRADEpro 2008) to generate a ’Summary
of findings’ table with information about outcomes, risk of bias,
and results of the meta-analyses. We used the GRADE system to
evaluate the quality of the evidence for outcomes reported in the
review considering the within-study risk of bias (methodological
quality), indirectness of evidence, diversity (heterogeneity), im-
precision of effect estimate, and risk of publication bias.
R E S U L T S
Description of studies
We included 14 randomised clinical trials in our analyses of ben-
efits and harms (Klotz 1989; Hermant 1991; Pomier-Layrargues
1994; Cadranel 1995; Gooday 1995; Van der Rijt 1995; Gyr
1996; Amodio 1997; Barbaro 1998; Zhu 1998; Giger-Mateeva
1999; Lacetti 2000; Dursun 2003; Li 2009). We identified one
randomised clinical trial which is currently ongoing (Yale 2014).
We are unable to determine if this ongoing randomised clinical
trial will be eligible for inclusion in the review. We excluded one
randomised clinical trial and 2 non-randomised studies from the
primary analyses, but included them in the evaluation of harms
(Marsepoil 1990; Kapczinski 1995; Jia 1999). For additional in-
formation, see Characteristics of included studies; Characteristics
of excluded studies; and Characteristics of ongoing studies tables.
Results of the search
We identified 249 references in the electronic andmanual searches
(Figure 2). After exclusion of duplicates and references to papers
that did not describe clinical trials assessing benzodiazepine re-
ceptor antagonists for hepatic encephalopathy, we retrieved 33
references for further assessment. Fourteen randomised clinical
trials described in 25 references fulfilled our inclusion criteria
(Klotz 1989; Hermant 1991; Pomier-Layrargues 1994; Cadranel
1995; Gooday 1995; Van der Rijt 1995; Gyr 1996; Amodio 1997;
Barbaro 1998; Zhu 1998; Giger-Mateeva 1999; Lacetti 2000;
Dursun 2003; Li 2009). In addition, we identified one ongoing
randomised clinical trial with an estimated completion date of
June 2017 (Yale 2014).
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Figure 2. Study flow diagram for identification and selection of randomised clinical trials.
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Two trials were letters (Klotz 1989; Hermant 1991), and 12
were full-text articles (Pomier-Layrargues 1994; Cadranel 1995;
Gooday 1995; Van der Rijt 1995; Gyr 1996; Amodio 1997;
Barbaro 1998; Zhu 1998; Giger-Mateeva 1999; Lacetti 2000;
Dursun 2003; Li 2009). The language of the publications was
English (Klotz 1989; Pomier-Layrargues 1994; Cadranel 1995;
Gooday 1995; Van der Rijt 1995; Gyr 1996; Amodio 1997;
Barbaro 1998; Giger-Mateeva 1999; Lacetti 2000; Dursun 2003),
Chinese (Zhu 1998; Li 2009), or French (Hermant 1991).
Included studies
Six trials used a parallel group (Hermant 1991; Gyr 1996; Zhu
1998; Lacetti 2000;Dursun 2003; Li 2009), and eight used a cross-
over design (Klotz 1989; Pomier-Layrargues 1994;Cadranel 1995;
Gooday 1995; Van der Rijt 1995; Amodio 1997; Barbaro 1998;
Giger-Mateeva 1999). In 3 cross-over trials, only people classified
as non-responders participated in the second cross-over treatment
period (Pomier-Layrargues 1994; Cadranel 1995; Barbaro 1998).
Six of the cross-over trials included awashout period,which ranged
from 3 minutes to 1 week (Pomier-Layrargues 1994; Gooday
1995; Van der Rijt 1995; Amodio 1997; Barbaro 1998; Giger-
Mateeva 1999).
The investigators diagnosed hepatic encephalopathy using clini-
cal scores, electrophysiological techniques, and psychometric tests
(Table 1; Table 2; Table 3). Nine randomised clinical trials in-
cluded participants with overt hepatic encephalopathy (Klotz
1989; Hermant 1991; Pomier-Layrargues 1994; Cadranel 1995;
Van der Rijt 1995; Barbaro 1998; Zhu 1998; Lacetti 2000; Li
2009). Six of these randomised clinical trials described precipitat-
ing events; the most common was gastrointestinal bleeding (Table
4). Three randomised clinical trials included participants with
minimal hepatic encephalopathy (Gooday 1995; Amodio 1997;
Giger-Mateeva 1999), while one included participants with either
minimal or overt hepatic encephalopathy (Dursun 2003). The
majority of the participants in the 14 included studies had cir-
rhosis although 30 (33%) of the 90 participants included in two
of the trials had fulminant hepatic failure (Van der Rijt 1995; Li
2009).
Recent ingestion of benzodiazepines was a stipulated exclusion
criterion in 10 randomised clinical trials with exclusion peri-
ods ranging from 3 days to 3 months (Hermant 1991; Pomier-
Layrargues 1994; Gooday 1995; Van der Rijt 1995; Amodio
1997; Barbaro 1998; Zhu 1998; Giger-Mateeva 1999; Lacetti
2000; Dursun 2003; Table 5). Nine randomised clinical trials
tested for blood/urine benzodiazepines at baseline (Hermant 1991;
Pomier-Layrargues 1994; Cadranel 1995; Van der Rijt 1995;
Gyr 1996; Amodio 1997; Barbaro 1998; Giger-Mateeva 1999;
Lacetti 2000); three randomised clinical trials stipulated negative
screening for blood/urine benzodiazepines as an inclusion crite-
rion (Hermant 1991; Van der Rijt 1995; Lacetti 2000), while the
proportion who tested positive for benzodiazepines in the other
6 randomised clinical trials ranged from 1.9% to 21%. The re-
maining five randomised clinical trials either stated that they did
not measure blood/urine benzodiazepines or else did not mention
testing (Table 5).
All randomised clinical trials compared intravenous flumazenil
versus placebo. The daily dose of flumazenil ranged from 0.2 mg
to 6.5 mg and the total dose from 0.2 mg to 19.5 mg. The dura-
tion of treatment ranged from 10 minutes to 72 hours. Five ran-
domised clinical trials evaluated the intervention effects at the end
of the intervention (Klotz 1989; Hermant 1991; Amodio 1997;
Giger-Mateeva 1999; Dursun 2003). Four randomised clinical tri-
als evaluated clinical outcomes at maximum of 24 to 72 hours after
the intervention (Pomier-Layrargues 1994; Cadranel 1995; Van
der Rijt 1995; Lacetti 2000). The remaining five randomised clin-
ical trials followed participants from 4 days to 4 weeks (Gooday
1995; Gyr 1996; Barbaro 1998; Zhu 1998; Li 2009).
The trials involving participants with overt hepatic encephalopa-
thy defined overall improvement of hepatic encephalopathy based
on a clinical assessment of mental status and the electroencephalo-
gram (Table 1). The trials involving participants with minimal
hepatic encephalopathy based their assessment of overall improve-
ment on a subjective assessment of ’alertness’ (Giger-Mateeva
1999); Number Connection Test results (Dursun 2003), the
Simple Reaction Time test results (Gooday 1995), or electroen-
cephalography (Van der Rijt 1995).
Excluded studies
We excluded one cross-over randomised clinical trial evaluating
cognitive function and anxiety in people with alcohol-related or
non-alcohol-related cirrhosis (Kapczinski 1995), one randomised
clinical trial evaluating flumazenil alone or with lactulose (Wu
2001), and seven observational studies (Grimm 1988; Bansky
1989;Marsepoil 1990; Devictor 1995;Ozyilkan 1997; Golubovic
1999; Jia 1999). None of the excluded studies reported data that
allowed analysis of serious adverse events.
One double-blind, cross-over trial involved participants with cir-
rhosis who were liver transplant candidates (Kapczinski 1995).
The objective of the trial was to evaluate the differential effects of
flumazenil versus placebo on cognitive function and anxiety in 10
people with alcohol-related cirrhosis, 10 people with non-alcohol-
related cirrhosis, and 10 healthy volunteers. None of the included
participants had evidence of overt hepatic encephalopathy. The
investigators evaluated a range of psychometric tests and reported
the results as group mean values. The trial report did not provide
information about the number of participants with abnormal test
results, but stated that participants with cirrhosis performedworse
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than people in the control group on several tests including verbal
recall, and on reaction time tasks. Treatment with flumazenil had
no effect on the test results, but induced anxiety in the participants
with non-alcoholic cirrhosis.
Two prospective non-randomised observational studies involved
47 participants with cirrhosis and overt hepatic encephalopathy (
Marsepoil 1990; Jia 1999). The first study included25participants
with alcohol-related cirrhosis and acute hepatic encephalopathy,
13 of whom received flumazenil in a dose of 0.2 mg intravenously
every 10 minutes until clinical improvement up to a maximum
total dose of 2 mg followed by a continuous maintenance infusion
of 0.3 mg. per hour for 48 hours.(Marsepoil 1990). The second
study included 22 participants with cirrhosis and overt hepatic
encephalopathy (Jia 1999), 12 of whom received flumazenil while
the remaining 10 received a traditional Chinese medicine, both
infused intravenously. The trial report stated that two participants
in the flumazenil group died of liver failure. The report did not
mention deaths in the control group.
A randomised clinical trial involving 20 participants with cirrhosis
and overt hepatic encephalopathy, 12 of whom were treated with
repeated bolus injections of flumazenil combined with lactulose
administered as a retention enema while a further eight partic-
ipants received flumazenil alone (Wu 2001). The study authors
defined improvement of hepatic encephalopathy as a three-point
or greater reduction in the Conn Score within six hours after the
administration of the interventions. Seven (58%) of the 12 partic-
ipants in the flumazenil plus lactulose group and 4 (50%) of the
eight participants in the flumazenil alone group showed improve-
ment. There were no reported deaths or adverse events.
We excluded five additional observational studies, involving 59
participants, 12 (20%) of whom were children (Grimm 1988;
Bansky 1989; Devictor 1995; Ozyilkan 1997; Golubovic 1999).
Two studies included participants with fulminant hepatic failure
(Grimm 1988; Devictor 1995), One study, involving 14 partic-
ipants with cirrhosis and overt hepatic encephalopathy reported
an improvement in mental status in 71% of participants within
minutes of receiving flumazenil which lasted for one to two hours;
six participants died (Bansky 1989). Another study, including 10
participants with cirrhosis and severe hepatic encephalopathy re-
ported transient improvements in themanifestations of hepatic en-
cephalopathy in 80% of the included participants; six died within
one year (Golubovic 1999). A third study evaluated the effects of
incremental intravenous boluses of flumazenil in 11 participants
with cirrhosis in whom baseline somatosensory evoked potentials
were abnormal; four (36%) showed a improvement in evoked po-
tentials with flumazenil (Ozyilkan 1997). One prospective study,
involving 15 adults and two children, reported transient improve-
ment in hepatic encephalopathy, after administration of flumaze-
nil, in four (44%) of nine participants with fulminant hepatic
failure and five (63%) of eight with cirrhosis (Grimm 1988). In
a study undertaken exclusively in children with fulminant liver
failure, awaiting emergency liver transplantation, flumazenil had a
transient beneficial effect on arousal in one child (Devictor 1995).
Risk of bias in included studies
We assessed the risk of bias based on published information and
on additional information from the trial investigators (Figure 3).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We classified 4 randomised clinical trials with adequate allocation
sequence generation and allocation concealment at low risk of se-
lection bias (Gooday 1995; Gyr 1996; Barbaro 1998; Zhu 1998).
The remaining 10 trials used an adequate method to conceal the
allocation, but they did not describe the allocation sequence gen-
eration (Klotz 1989; Hermant 1991; Pomier-Layrargues 1994;
Cadranel 1995; Van der Rijt 1995; Amodio 1997; Giger-Mateeva
1999; Lacetti 2000; Dursun 2003; Li 2009).
Blinding
We classified all randomised clinical trials as having a low
risk of performance and detection bias as they were double-
blind and placebo-controlled with blinding of participants, per-
sonnel, and outcome assessors (Klotz 1989; Hermant 1991;
Pomier-Layrargues 1994; Cadranel 1995; Gooday 1995; Van der
Rijt 1995; Gyr 1996; Amodio 1997; Barbaro 1998; Zhu 1998;
Giger-Mateeva 1999; Lacetti 2000; Dursun 2003; Li 2009).
Incomplete outcome data
Two randomised clinical trials gave the impression that there were
no missing outcome data although this was not specifically stated
(Hermant 1991; Zhu 1998). The remaining trials had no missing
outcome data and included all participants in the reported analyses
(Klotz 1989; Pomier-Layrargues 1994; Cadranel 1995; Gooday
1995; Van der Rijt 1995; Gyr 1996; Amodio 1997; Barbaro 1998;
Giger-Mateeva 1999; Lacetti 2000; Dursun 2003; Li 2009).
Selective reporting
We did not have access to protocols and were, therefore, unable to
evaluate any potential differences between outcomes described in
protocols compared with trial publications. All randomised clin-
ical trials included a description of the outcomes all-cause mor-
tality and hepatic encephalopathy (Klotz 1989; Hermant 1991;
Pomier-Layrargues 1994; Cadranel 1995; Gooday 1995; Van
der Rijt 1995; Gyr 1996; Amodio 1997; Barbaro 1998; Zhu
1998;Giger-Mateeva 1999; Lacetti 2000;Dursun 2003; Li 2009).
Therefore, we classified all trials at low risk of reporting bias.
For-profit funding
Pharmaceutical companies provided financial or other support for
5 of the randomised clinical trials (Pomier-Layrargues 1994; Van
der Rijt 1995; Cadranel 1995; Gyr 1996; Zhu 1998). Seven trials
did not provide information about funding (Klotz 1989; Hermant
1991; Gooday 1995; Giger-Mateeva 1999; Lacetti 2000; Dursun
2003; Li 2009). The remaining 2 trials did not receive support
from pharmaceutical companies (Amodio 1997; Barbaro 1998).
Other potential sources of bias
One randomised clinical trial simplified the intervention regimen
and assessment of outcomes after the inclusion of 9 of 18 partic-
ipants (Van der Rijt 1995). We classified this trial at unclear risk
of other bias and the remaining trials at low risk of bias (Klotz
1989; Hermant 1991; Pomier-Layrargues 1994; Cadranel 1995;
Gooday 1995;Gyr1996; Amodio 1997; Barbaro 1998;Zhu1998;
Giger-Mateeva 1999; Lacetti 2000; Dursun 2003).
Overall risk of bias
We classified one randomised clinical trial at low risk of bias for
all domains (Barbaro 1998), and the remaining trials at high risk
of bias (Klotz 1989; Hermant 1991; Pomier-Layrargues 1994;
Cadranel 1995; Gooday 1995; Van der Rijt 1995; Gyr 1996;
Amodio 1997; Zhu 1998; Giger-Mateeva 1999; Lacetti 2000;
Dursun 2003; Li 2009).
Effects of interventions
See: Summary of findings for the main comparison
Flumazenil versus placebo for people with cirrhosis and hepatic
encephalopathy
The total number of participants was 867. Three cross-over ran-
domised clinical trials did not report outcomes for the first in-
tervention period (Gooday 1995; Amodio 1997; Giger-Mateeva
1999);we received information about the number of participants
and all-cause mortality rates during the first allocation period for
one of these trials (Gooday 1995), but not for the remaining two
(Amodio 1997; Giger-Mateeva 1999).We were able to gather data
from the first allocation period for the 5 remaining cross-over trials
and required data from all of the parallel-arm trials. Accordingly,
our analyses included 842 participants.
Primary outcomes
All-cause mortality
In total, 32/433 participants allocated to flumazenil versus 38/409
participants allocated to placebo died (RR 0.75, 95% CI 0.48 to
1.16; 11 trials; I2 = 0%; Analysis 1.1). The trial classified as low
risk of bias found no beneficial or detrimental effect of flumazenil
on all-cause mortality (RR 0.76, 95% CI 0.37 to 1.53; Analysis
1.2). There was no evidence of small-study effects (P = 0.31). The
Trial Sequential Analyses ignored three randomised clinical trials
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due to insufficient information indicating that we have insufficient
evidence to support or refute an effect of flumazenil on all-cause
mortality (Cadranel 1995; Gyr 1996; Zhu 1998; Figure 4). The
trials including participants with minimal hepatic encephalopathy
did not report any deaths (Gooday 1995; Dursun 2003; Analysis
1.1). There were no differences between trials involving partici-
pants with cirrhosis compared with trials involving participants
with cirrhosis or fulminant hepatic failure (Analysis 1.11). Addi-
tional analyses showed no differences between trials using a cross-
over or a parallel-arm design (Analysis 1.3); or between trials with
short-term or long-term (> 1 day) follow-up (Analysis 1.4).
Figure 4. Trial Sequential Analysis of randomised clinical trials evaluating flumazenil versus placebo for
people with cirrhosis and hepatic encephalopathy. The outcome is hepatic encephalopathy. The original meta-
analysis included 11 randomised clinical trials with 824 participants. The Trial Sequential Analysis is made with
alpha 3%, power 90%, relative risk reduction 20%, assumed control risk 60%, and diversity 10%. The blue line
(Z-curve) corresponds to the cumulative meta-analysis, the black horizontal line is the conventional boundary
(3% level of significance), and the inward sloping green line is the Trial Sequential Monitoring Boundary. The
analysis found that the Z-curve crossed the monitoring boundary before reaching the diversity-adjusted
required information size of 914 participants.
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Hepatic encephalopathy
Analysis of the data on 824 participants involved in nine ran-
domised clinical trials showed that flumazenil was associated with
a beneficial effect on hepatic encephalopathy (RR 0.75, 95% CI
0.71 to 0.80; I2 = 0%; Analysis 1.5). The analysis only included
10 participants with minimal hepatic encephalopathy. The trial
classified as having a low risk of bias found a beneficial effect of
flumazenil on hepatic encephalopathy (RR 0.78, 95% CI 0.72 to
0.84; Analysis 1.6). In the Trial Sequential Analysis, the Z-curve
crossed the monitoring boundary (see Figure 4 for additional in-
formation). The analysis found that the diversity adjusted infor-
mation size was 914 participants. The information size was 1028
participants when we increase the diversity to 20% (the model
based diversity was 0%). The subgroup analyses showed no dif-
ferences between subgroups of trials including participants with
cirrhosis or fulminant hepatic failure (Analysis 1.9), or trials strat-
ified by their design (Analysis 1.7), or their duration of follow-up
(Analysis 1.8).
Serious adverse events
We were only able to conduct analyses for fatal serious adverse
event (Table 6). In the largest randomised clinical trial (Barbaro
1998), 13 nonresponders in the flumazenil group and 17 nonre-
sponders in the placebo group died within 3 to 4 days (range 2 to
6). The causes of death were septic shock (n = 20); hypovolaemic
shock (n = 8) and lactic acidosis (n = 2), but information was
not provided on the number of deaths by cause in each group. In
a smaller randomised clinical trial, 4 of 28 participants allocated
to flumazenil and 5 of 21 participants allocated to placebo died
within 4 weeks of the trial (Gyr 1996). One participant in the
placebo group died with respiratory failure during the course of
the trial, but the causes of death in the remaining eight partici-
pants were not provided. Three trials reported all-cause mortality
in the flumazenil and control groups without providing informa-
tion about the cause of death (Zhu 1998; Lacetti 2000; Li 2009).
None of the included participants experienced seizures.
Secondary outcome measures
None of the included trials assessed health-related quality of life.
We were unable to conduct a meta-analysis of non-serious ad-
verse events. Four randomised clinical trials reported that none of
the included participants experienced non-serious adverse events
(Hermant 1991; Barbaro 1998; Lacetti 2000; Dursun 2003). In
one trial, four participants in the flumazenil group experienced
nausea, vomiting, flushing, or irritability (Gyr 1996); the total
number of participants with the individual adverse events was not
described. Two participants in one trial had transient palpitations,
but the intervention group was not specified (Zhu 1998). One
cross-over trials reported that one in 10 participants felt drowsy,
possibly after flumazenil infusion (Giger-Mateeva 1999).
Exploratory outcomes
We were able to include Number Connection Test results from
one randomised clinical trial with 40 participants. The trial found
a MD of -3.79 seconds (95% CI -32.14 to 24.56; Analysis 1.10).
’Summary of findings’ table
As shown in the Summary of findings for themain comparison, we
downgraded the strength of the evidence to low based on method-
ological concerns.
D I S C U S S I O N
Summary of main results
This review included 14 randomised clinical trials published be-
tween 1989 and 2009. The primarymeta-analyses showed no ben-
eficial or detrimental effect of flumazenil on all-cause mortality,
but it showed a potential short-term beneficial effect of flumazenil
on the manifestations of hepatic encephalopathy. We found little
evidence suggesting that flumazenil was associated with serious
adverse effects, However, the reporting of serious and non-serious
adverse events was generally incomplete or unclear, and our anal-
yses of adverse events may be subject to outcome reporting bias.
Based on methodological concerns, we classified the strength of
the evidence as low. Therefore, our review remains inconclusive.
Overall completeness and applicability of
evidence
Flumazenil is a short-acting specific benzodiazepine antagonist
which acts by inhibiting activity at the benzodiazepine recogni-
tion site on the GABA/benzodiazepine receptor complex. Its oral
bioavailability is poor and hence intravenous administration is
necessary (Brogden 1991). The main indication for flumazenil is
the reversal of benzodiazepine overdose or prolonged anaesthesia.
Based on pharmacological studies, the onset of its effect is rapid
and its duration of action is short (Brogden 1991). In healthy peo-
ple, the half-life is 50 minutes. Thus, repeated low intravenous
doses or continuous infusion is needed if the clinical situation re-
quires a longer lasting effect (Hood 2014). Hepatic encephalopa-
thy is characterised by an increase in GABA-A tone which is the
rationale for use of flumazenil in this condition.
The most important outcomes for people with cirrhosis and hep-
atic encephalopathy include mortality, morbidity, adverse events,
and health-related quality of life (Bajaj 2011). We found no detri-
mental or beneficial effect on all-cause mortality or adverse events
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but a potential short-term effect on the manifestations of hepatic
encephalopathy. There was no reported information on health-
related quality of life. However, the applicability of the evidence
will be limited because of the need for intravenous administra-
tion. Most trials evaluated single or repeated bolus injections
(Klotz 1989; Hermant 1991; Pomier-Layrargues 1994; Cadranel
1995; Gooday 1995; Amodio 1997; Barbaro 1998; Zhu 1998;
Giger-Mateeva 1999; Lacetti 2000). One trial assessed the effect
of a 72-hour infusion of flumazenil (Van der Rijt 1995), but the
investigators changed the intervention to bolus injections because
participants found the three-day infusion too stressful. None of
the trials compared different doses or different modes of admin-
istration. We found no effect of the dose of flumazenil on the es-
timated effect on all-cause mortality or hepatic encephalopathy.
However, based on the limited number of events and trials, impor-
tant clinical differences may have been overlooked. The half-life of
flumazenil is prolonged up to 2.4 hours in people with moderate
to severe hepatic decompensation, hence providing some prolon-
gation of action (Amrein 1990). However, we found no further
or additional effects of flumazenil when analysing trials with more
than 24-hour follow-up.
The majority of the included randomised clinical trials enrolled
participants with cirrhosis and an acute episode of hepatic en-
cephalopathy although the severity varied between trials. Episodes
of hepatic encephalopathy often develop in response to a precipi-
tating event such as gastrointestinal bleeding, which was the most
common precipitant identified in the included trials in this review.
Identification and treatment of precipitating factors is key to the
management of affected people (EASL/AASLD guideline 2014a;
EASL/AASLD guideline 2014b). We did not have sufficient data
to assess potential difference between precipitated and non-pre-
cipitated hepatic encephalopathy. None of the included partici-
pants had surgically created or transjugular intrahepatic portosys-
temic shunts. Likewise, the review contained very little informa-
tion about people with recurrent or persistent (chronic) hepatic
encephalopathy. Two trials included a small number of partici-
pants with fulminant hepatic failure (Van der Rijt 1995; Li 2009).
This condition is infrequent in clinical practice. We were unable
to gather data that allowed us to evaluate any differential effects
of flumazenil on hepatic encephalopathy associated with acute or
chronic liver failure. However, subgroup analyses based on aggre-
gated data found no difference between trials including or not in-
cluding participants with fulminant hepatic failure. Nevertheless,
it is likely that the pathophysiology of hepatic encephalopathy in
participants with acute liver failure differs from that associated
with cirrhosis. Three trials enrolled people with minimal hepatic
encephalopathy (Gooday 1995; Amodio 1997; Giger-Mateeva
1999), while a further trial included participants with both mini-
mal and low-grade acute hepatic encephalopathy (Dursun 2003).
In these four trials, the objective appears to be more mechanistic
than therapeutic, but based on our subgroup analysis, we found
no difference in outcomes between overt and minimal hepatic
encephalopathy. However, the diagnostic end points for hepatic
encephalopathy in these trials were very different, namely clinical
assessment versus psychometry, and the number of trials was small
so that statistical differences may be overlooked.
Prior intake of benzodiazepines may influence the effects of
flumazenil. Ten randomised clinical trial stipulated prior in-
gestion of benzodiazepines as an exclusion criterion (Hermant
1991; Pomier-Layrargues 1994; Gooday 1995; Van der Rijt 1995;
Amodio 1997; Barbaro 1998; Zhu 1998; Giger-Mateeva 1999;
Lacetti 2000; Dursun 2003), while nine trials undertook baseline
screening for benzodiazepines (Hermant 1991; Pomier-Layrargues
1994; Cadranel 1995; Van der Rijt 1995; Gyr 1996; Amodio
1997; Barbaro 1998; Giger-Mateeva 1999; Lacetti 2000). Three
randomised clinical trials stipulated negative testing for benzodi-
azepines as an inclusion criterion (Hermant 1991; Van der Rijt
1995; Lacetti 2000). In the remaining six trials, in which baseline
testing was undertaken, it was unclear whether the results were
available at the time of randomisation or whether participants were
included irrespective of the results; in two of these trials, none
of the participants tested positive (Amodio 1997; Giger-Mateeva
1999), while in the remaining four trials, between 1.9% and
21.4% of participants tested positive (Pomier-Layrargues 1994;
Cadranel 1995; Gyr 1996; Barbaro 1998). Thus, the exclusion of
participants based on reports of non-ingestion of benzodiazepines
is clearly unreliable. In all four of these trials, the assessment of
outcomes in relation to the presence/absence of benzodiazepines
were related to the response to flumazenil rather than to inter-
vention allocation (Pomier-Layrargues 1994; Cadranel 1995; Gyr
1996; Barbaro 1998). All four showed that the majority of partic-
ipants who responded to flumazenil did not have detectable cir-
culating benzodiazepines whereas some non-responders had mea-
surable quantities of these substances in their blood. The trials
concluded that the presence of benzodiazepines was not predictive
of participants’ responses to flumazenil. We did not find this in-
formation in 5 trials, which should be considered when evaluating
their results (Klotz 1989; Gooday 1995; Zhu 1998; Dursun 2003;
Li 2009).
Administration of flumazenil by sublingual lozenge and topical
cream has also been tested, albeit very selectively (Rye 2012); the
preparations are not generally available nor applicable for use in
most clinical settings and is not tested in clinical trials evaluating
participants with hepatic encephalopathy.
On the basis of this review, the use of flumazenil in the manage-
ment of hepatic encephalopathy would be limited. It might be of
value in people with severe hepatic encephalopathy not respond-
ing to usual management to facilitate procedures or to allow as-
sessment of cognitive status in potential transplant candidates if
other conditions, such as hypoxic injury, are suspected.
Quality of the evidence
The review is limited because of methodological and statistical is-
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sues relating to the included randomised clinical trials. Seven of
the 14 included trial used a cross-over design (Pomier-Layrargues
1994; Cadranel 1995; Gooday 1995; Van der Rijt 1995; Amodio
1997; Barbaro 1998; Giger-Mateeva 1999). While this design is
suitable for evaluating interventions which are predicted to have a
temporary effect on chronic stable conditions, it is not suitable for
evaluating interventions which have a short-term effect in unsta-
ble conditions (Rosenkranz 2015). The majority of trials in this
review included participants with an acute episode of hepatic en-
cephalopathy, and thus, a cross-over design is not appropriate. The
problem was further compounded since some of the trials used a
modified design with cross-over of only the non-responders to the
second treatment period. Therefore, inclusion of both periods in
our analyses would introduce potential bias and would have posed
statistical problems. We included data from the first period of the
seven cross-over trials, obtaining the data which correspond to
those available from the more suitable parallel-armed randomised
clinical trials. The drawback of the strategy is loss of information
from the second period. A further problem with the cross-over
design is that it precludes an assessment of risk of relapse.
Only one trial was at low risk of bias in the overall assessment
(Barbaro 1998). The trial included the largest number of partic-
ipants and had a weight of 39% in the analysis of mortality and
56% in the analysis of hepatic encephalopathy. We found no dif-
ference between this trial and the remaining trials with a high risk
of bias for the two outcomes based on the test for subgroup differ-
ences; exclusion of the trial did not change the overall conclusion.
We found no evidence of publication bias or other small-study ef-
fects and between-trial heterogeneity was negligible. Nevertheless,
the CIs were wide. Although these findings support the quality of
the evidence, we still have potential problems with the use of the
cross-over design. We classified the quality of the evidence as low.
While most trials reported mortality and hepatic encephalopathy,
the quality of the reporting of both non-fatal serious and non-seri-
ous adverse events was low. We looked for additional information
about harms in observational studies, but were unable to retrieve
and analyse adverse events in the studies identified.
Potential biases in the review process
We attempted to minimise possible selection biases by using a
comprehensive search strategy. Searches in electronic databases
were combined with extensive handsearches. In addition, we also
searched conference proceedings and abstract books. We think it
likely that we have not missed published trials, but we cannot ex-
clude the possibility that we have missed unpublished trials. The
intervention is not high-profile and it is possible that negative tri-
als, particularly if small, will not have appeared as abstracts at con-
ferences or been published in full. However, our meta-regression
analyses showed no evidence of publication bias or other dissem-
ination biases.
Agreements and disagreements with other
studies or reviews
One meta-analysis undertaken in 2002 (Goulenok 2002) in-
cluded 6 randomised clinical trials with 641 participants (Pomier-
Layrargues 1994; Cadranel 1995; Van der Rijt 1995; Groeneweg
1996; Gyr 1996; Barbaro 1998). The mean percentages of people
with clinical improvement (5 trials) were 27% in treated groups
and 3% in placebo groups. We believe that two of these involve
the same population of participants (Groeneweg 1996;Gyr 1996).
The first trial included 49 participants with mild to moderate
(Grade I to III) hepatic encephalopathy (Gyr 1996), while the sec-
ond trial, which is described by the authors as an ancillary study,
reported electroencephalography data from 32 of the original 49
participants (Groeneweg 1996).We excluded the second trial from
this review.
The previous version of this review included 13 randomised clin-
ical trials with 805 participants (Als-Nielsen 2004). This earlier
review found no effect of flumazenil on all-cause mortality based
on an analysis of 10 trials and a beneficial effect on hepatic en-
cephalopathy based on an analysis of 8 trials with a risk differ-
ence of 0.28 (95% CI 0.20 to 0.37). We have updated the review
by inclusion of two additional randomised clinical trials in the
analyses of benefits, and the addition of one previously included
randomised clinical trial and two observational studies in our as-
sessment of harms. Our analysis of all-cause mortality included 13
trials and the analysis of hepatic encephalopathy included 9 trials.
In agreement with the previous review, we found no effect on all-
cause mortality and a beneficial effect on hepatic encephalopathy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes randomised clinical trials evaluating the treat-
ment of hepatic encephalopathy. The analyses found some evi-
dence that flumazenil may be associated with a short-term effect
on hepatic encephalopathy, but no beneficial effect on impor-
tant clinical outcomes such as all-cause mortality, serious adverse
events, or health-related quality of life. Likewise, we are unable
to determine the risk of non-fatal serious or non-serious adverse
events based on the available evidence.
Implications for research
We used the EPICOT format to define the implications of our
review for research (Brown 2006). Overall, the evidence is insuf-
ficient and additional evidence from randomised clinical trials is
needed to evaluate whether flumazenil has a clinically relevant ef-
fect on hepatic encephalopathy.
Evidence (what is the current state of the evidence?): this review
includes 14 randomised clinical trials and found low quality evi-
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dence that flumazenil may have a beneficial short-term effect on
hepatic encephalopathy. The evidence concerning all-cause mor-
tality, non-fatal serious adverse events, and non-serious adverse
events is insufficient.
Participants (what is the population of interest?): the largest body
of evidence evaluated people with cirrhosis and an acute episode of
overt hepatic encephalopathy. Only a relatively small proportion
had minimal hepatic encephalopathy and chronic overt hepatic
encephalopathy; very few had acute liver failure.
Interventions (what are the interventions of interest?): flumazenil.
Comparisons (what are the comparisons of interest?): placebo-
controlled randomised clinical trials.
Outcomes (what are the outcomes of interest?): all-causemortality,
hepatic encephalopathy, and adverse events; evidence evaluating
the effect on health-related quality of life is also needed.
Time stamp (date of literature search): May 2017.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amodio 1997
Methods Double-blind, single-centre, placebo-controlled RCT.
Cross-over design: all participants underwent both intervention periods (received
flumazenil and placebo)
Participants 13 participants with cirrhosis with no evidence of overt hepatic encephalopathy but
with abnormal brainstem evoked potentials (5 participants) or prolonged Number Con-
nection Test times (6 participants), or both at baseline corresponding to a diagnosis of
minimal hepatic encephalopathy
Mean ± SD age: flumazenil/placebo: 54 ± 7 years.
Proportion of men: 77%.
Aetiology of cirrhosis: alcohol 77%; hepatitis B/C 15%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 0%.
Interventions Intervention comparison: intravenous bolus flumazenil 1 mg followed by 4 boluses of
0.5 mg every 30 minutes versus placebo (saline)
Total dose of flumazenil: 3 mg.
Washout period: 72 hours before cross-over to the alternative arm.
Cointerventions: none described.
Outcomes Outcomes included in meta-analyses: none.
Neuropsychiatric assessment Baseline and post infusion:
• Brainstem auditory evoked potentials;
• Number Connection Test.
Inclusion period (date) Not described.
Country Italy.
Notes Included data: RCT did not describe outcomes for first intervention period. Therefore,
we were unable to include the trial in our meta-analyses. The study report includes 2
tables containing data for the 5 participants with abnormal evoked potentials at baseline
and the 6 participants with abnormal Number Connection Test times. There were no
change in the group mean variables after flumazenil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Low risk Concealed drug containers.
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Amodio 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Low risk Funding from the ItalianLiver Foundation.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Barbaro 1998
Methods Double-blind, multi-centre, placebo-controlled RCT.
Cross-over design: investigators crossed-over participants who did not respond to in-
tervention during first period (remained in Grade III or IVa coma) to alternative inter-
vention
Participants 527 participants with cirrhosis and overt hepatic encephalopathy (Grades III or IVa;
Table 2), admitted to an intensive care unit. Diagnostic criteria corresponded to acute
hepatic encephalopathy. Precipitating factors are described (Table 4).
Mean ± SD age (grade III/IVa): flumazenil: 56 ± 11.5/53 ± 12 years; placebo: 48 ± 20/
55 ± 13.5 years
Proportion of men: 69%.
Aetiology of cirrhosis: alcohol 40%; hepatitis B/C 59%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 10/527 (1.9%)
participants.
Interventions Intervention comparison: intravenous infusion flumazenil 1 mg given over 3 to 5
minutes versus placebo (isotonic saline)
Total dose of flumazenil: 1 mg.
Cointerventions: lactulose 30 mL every 6 hours via nasogastric tube; antibiotics were
given to 22 participants with sepsis in the flumazenil group and 8 in the placebo group
Outcomes Outcomes included inmeta-analyses:mortality, hepatic encephalopathy (Table 1), and
serious adverse events (Table 6) assessed for a maximum of 4 days after randomisation.
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Barbaro 1998 (Continued)
Neuropsychiatric assessment Baseline and post infusion:
• Coma grade at baseline (Table 2);
• Modified Glasgow Coma Scale (Table 2) assessed at 10 minutes before and every
10 minutes after the intervention for a maximum of 3 hours;
• Continuous electroencephalography recorded 15 minutes before and 10 minutes
after the infusion (Table 3).
Inclusion period (date) January 1993 to December 1997.
Country Italy.
Notes Included data: Serum benzodiazepines were detected in 10 participants (4 with Grade
III and 6 with Grade IVa coma). The published paper provides no information about the
distribution of these participants to flumazenil or placebo during the first intervention
period. Therefore, we were unable to exclude these participants from the analyses. The
trial reported on several serious adverse events (Table 6).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequential list of
block-randomised assignments
Allocation concealment (selection bias) Low risk Concealed ampoules of flumazenil and
placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel us-
ing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment using
placebo.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants included in analyses
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Low risk No information provided.
Other bias Low risk No other biases.
Overall assessment Low risk Low risk of bias.
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Cadranel 1995
Methods Double-blind, single-centre, placebo-controlled RCT.
Cross-over design: participants who did not respond after 10 minutes during the first
period received the alternative intervention
Participants 14 participants with cirrhosis experiencing 18 separate episodes of acute hepatic en-
cephalopathy classified as Grade II to IV (Table 2). Precipitating factors are described
(Table 4).
Mean ± SD age: whole group 54.8 ± 7.7 years.
Proportion of men: 71%.
Aetiology of cirrhosis: alcohol 71%; hepatitis B/C 29%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 3/14 (21.4%)
participants.
Interventions Intervention comparison: continuous intravenous infusion flumazenil 0.1 mg/mL at 1
mL/minute flumazenil versus placebo (sodium edetate 1 mg). Investigators stopped the
infusion after 10minutes if participants showed improvement in electroencephalography
or coma grade
Total dose of flumazenil: 1 mg.
Cointerventions: none described.
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed after maximum of 3 days.
Neuropsychiatric assessment Baseline and post infusion:
• Clinical assessment of mental status (Table 2) assessed at baseline and within 100
minutes after infusion;
• Electroencephalography graded using a 5-point scale (Table 3) assessed at baseline
and within 10 minutes after infusion.
Inclusion period (date) May 1988 to May 1990.
Country France.
Notes Included data: the trial included 14 participants who between them experienced 18
episodes of acute hepatic encephalopathy. 1 participant entered the trial once and 1
entered the trial 3 times. We included data from the first intervention period in our
analyses. The published report described the number of participants who died after the
second treatment period only (Table 6).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Concealed drug vials.
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Cadranel 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were complete.
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in original pro-
tocol or information in trial registries
For-profit funding High risk Hoffmann-La Roche Ltd. supplied
flumazenil and placebo.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Dursun 2003
Methods Double-blind, single-centre, placebo-controlled, parallel-arm RCT
Participants 40 participants with cirrhosis and hepatic encephalopathy classified as subclinical (cor-
responding to minimal; 10 participants) or overt Grade I to III (30 participants; Table
2). Type of overt hepatic encephalopathy (acute or chronic) not specified
Mean ± SD age: flumazenil: 44.5 ± 12.9 years; placebo: 43.7 ± 11.9 years.
Proportion of men: 73%.
Aetiology of cirrhosis: alcohol 0%; hepatitis B/C 100%.
Proportion testing positive for benzodiazepines at baseline (Table 5): investigators
did not screen for benzodiazepines.
Interventions Intervention comparison: intravenous infusion flumazenil 1mg/hour for 5 hours versus
placebo (saline) administered similarly
Total dose of flumazenil: 5 mg.
Cointerventions: lactulose 30 mL 6-hourly
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
serious adverse events (Table 6), and Number Connection Test assessed after a maximum
of 5 hours
Neuropsychiatric assessment Baseline and post infusion:
• Clinical assessment of mental status (Table 2) assessed at baseline and every 30
minutes after infusion for a maximum of 5 hours;
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Dursun 2003 (Continued)
• Glasgow Coma Score (Table 2) assessed at baseline;
• Electroencephalography (Table 3) assessed at baseline and 1 hour after infusion;
• Number Connection Test assessed at baseline and every 30 minutes after infusion
for a maximum of 5 hours;
• Blood ammonia concentrations assessed at baseline.
Inclusion period (date) December 1999 to January 2002.
Country Turkey.
Notes Included data: the trial report included information about participants with minimal
and overt hepatic encephalopathy. We have analysed these 2 groups separately
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Concealed drug containers.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants are included in analyses
Selective reporting (reporting bias) Low risk Trial describes clinically relevant outcomes.
Wehadno access to information about out-
comes described in the original protocol or
information in trial registries
For-profit funding Unclear risk No information provided.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
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Giger-Mateeva 1999
Methods Double-blind, single-centre, placebo-controlled RCT.
Cross-over design: investigators crossed over all participants to the alternative interven-
tion
Participants 10 participants with cirrhosis and no clinical evidence of overt hepatic encephalopathy; 5
participants hadminimal hepatic encephalopathy based on the finding of either abnormal
visual evoked potentials or Number Connection Test results
Age (range): 40 to 60 years.
Proportion of men: 80%.
Aetiology of cirrhosis: alcohol 30%; hepatitis B/C 70%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 0%.
Interventions Intervention comparison: intravenous infusion flumazenil 1 mg over 2 minutes versus
placebo
Total dose of flumazenil: 1 mg.
Washout period: 4 hours.
Cointerventions: none reported.
Outcomes Outcomes included in meta-analyses: none.
Neuropsychiatric assessment At baseline and post infusion:
• Visual evoked potential at baseline and every 8, 16, 24, 32, and 40 minutes after
infusion;
• Visual reaction time at baseline and 5, 10, and 20 minutes after infusion;
• Auditory reaction time at baseline and 5, 10, and 20 minutes after infusion;
• Number Connection Test at baseline and 10 minutes after infusion.
Inclusion period (date) Not described.
Country The Netherlands.
Notes Included data: trial did not include separate information about the first allocation
period. Therefore, we were unable to include the trial in our meta-analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Low risk Concealed drug containers.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
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Giger-Mateeva 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The trial describes clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Gooday 1995
Methods Double-blind, single-centre, placebo-controlled RCT.
Cross-over design: all participants were crossed over to alternative intervention
Participants 10 participants with cirrhosis and subclinical (corresponding to minimal) hepatic en-
cephalopathy diagnosed based on a score on the Digit Symbol Substitution test of < 1
SD of the age-matched normative mean
Mean age ± SD: 53.9 ± 7.4 years.
Proportion of men: 80%.
Aetiology of cirrhosis: alcohol 60%; hepatitis B/C 20%.
Proportion testing positive for benzodiazepines at baseline (Table 5): apparently not
performed (not specifically stated).
Interventions Intervention comparison: intravenous infusion flumazenil 0.2 mg over an unspecified
time versus placebo (saline)
Total dose of flumazenil: 0.2 mg.
Washout period: 1 week.
Cointerventions: none described.
Outcomes Outcomes included in meta-analyses: mortality and serious adverse events (Table 6)
assessed at end of the intervention.
Neuropsychiatric assessment At baseline:
• Digit Symbol Substitution Test.
At baseline and post infusion:
• Simple reaction time;
• Complex reaction time;
• Auditory Verbal Learning Test;
• Digit Symbol Substitution Test;
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Gooday 1995 (Continued)
• Digits forward and backwards.
Duration of follow-up and timing of tests not described.
Inclusion period (date) Not described.
Country UK.
Notes Included data: we received additional (unpublished) information about the trial meth-
ods and number of participants allocated to flumazenil/placebo during the first alloca-
tion period via email in 2003 when conducting the previous version of this review. The
trial did not evaluate the number of participants with an overall improvement in hepatic
encephalopathy. Therefore, we were unable to include the trial in our analyses of this
outcome measure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Serially numbered opaque sealed envelopes
used in administration of concealed drug
containers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias High risk Primary investigators described a signifi-
cant drug by order and group by drug by
order interaction
Overall assessment High risk High risk of bias.
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Gyr 1996
Methods Double-blind, multi-centre, parallel-arm, placebo controlled RCT
Participants 49 participants with cirrhosis and chronic overt hepatic encephalopathy (Grades I to III;
Table 2).
Mean age ± SD: flumazenil: 55.5 ± 9.4 years; placebo: 53.6 ± 10.3 years.
Proportion of men: 69%.
Aetiology of cirrhosis: alcohol 51%; hepatitis B/C 35%.
Proportion testingpositive for benzodiazepines at baseline (Table 5):11% influmaze-
nil group; 5% in placebo group.
Interventions Intervention comparison: intravenous boluses of flumazenil 0.4 mg, 0.8 mg, and 1
mg at 1-minute intervals followed by a 3-hour infusion of flumazenil 1 mg/hour versus
placebo (saline)
Total dose of flumazenil: 5.2 mg.
Cointerventions: none reported.
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed after a maximum of 4 weeks.
Neuropsychiatric assessment Baseline and post infusion:
• Clinical assessment of mental status (Table 2) at baseline and every 30 minutes for
5 hours then every 1 hour until 12 hours post infusion;
• Continuous (20 minutes) electroencephalography immediately after the infusion
and then at 2 hours 40 minutes, 3 hours, and 7 hours 40 minutes post infusion (Table
3).
Inclusion period (date) Not reported.
Country Switzerland (primary), France, Germany, Italy, Canada, the Netherlands, the UK, and
Korea
Notes Included data: authors reported intention-to-treat analyses including all participants
randomised and a per-protocol analysis excluding protocol violators (25 participants).
We included data on all participants in our analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers.
Allocation concealment (selection bias) Low risk Sealed envelopes used in double-blind ad-
ministration of flumazenil and placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and personnel.
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Gyr 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding High risk Support from Hoffmann-La Roche Ltd.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Hermant 1991
Methods Double-blind, parallel-arm, single-centre, placebo-controlled RCT
Participants 12 participants with cirrhosis and an acute episode of hepatic encephalopathy defined
as Grade IIIa with severely abnormal electroencephalography changes, but a Glasgow
Coma Score of < 12 (Table 2).
Proportion of men: not reported.
Mean age ± SD: whole group 58.2 ± 5.4 years.
Aetiology of liver disease: not reported.
Proportion testing positive for benzodiazepines at baseline (Table 5): 0%.
Interventions Intervention comparison: intravenous infusion flumazenil 0.2 mg/kg over 10 minutes
versus placebo (saline)
Total dose of flumazenil: 0.2 mg/kg.
Cointerventions: none described.
Outcomes Outcomes included in meta-analyses: mortality (Table 6) and serious adverse events
(Table 6).
Neuropsychiatric assessment Baseline and post infusion:
• Glasgow Coma Scale (Table 2);
• Electroencephalography (Table 3).
The timing of assessments post infusion was not described.
Inclusion period (date) Not described.
Country France.
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Hermant 1991 (Continued)
Notes Included data: the trial report did not specifically state the number of participants
with (or without) improvement in hepatic encephalopathy separately for the allocation
groups. Therefore, we were unable to include the trial in the analysis of this outcome
measure
Article published in French (full translation available).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Concealed drug containers.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Trial report gave the impression that there
were no missing outcome data although
this was not specifically stated
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Klotz 1989
Methods Double-blind, cross-over, single-centre, placebo-controlled RCT
Participants 2 participants with cirrhosis and stable hepatic encephalopathy (Grade III). Description
corresponded to chronic overt hepatic encephalopathy although this was not specifically
stated
Proportion of men: not reported.
Mean age: not reported.
Aetiology of liver disease: alcohol 100%.
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Klotz 1989 (Continued)
Proportion testing positive for benzodiazepines at baseline (Table 5): apparently not
performed (not specifically stated).
Interventions Intervention comparison: intravenous infusion flumazenil 1 mg over 1 minute versus
placebo
Total dose of flumazenil: 1 mg.
Washout period: not specified.
Cointerventions: not reported.
Outcomes Outcomes included in meta-analyses: mortality and serious adverse events (Table 6)
assessed for a maximum of 2 hours post interventions.
Neuropsychiatric assessment Clinical assessment of mental status: assessed after 2 hours (no specific score; timing
not specified)
Inclusion period (date) Not described.
Country Germany.
Notes Included data: investigators described the design as cross-over but did not provide data
from the first intervention period. Therefore, we were unable to include the trial in our
analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trial described as double blind and placebo
controlled. However, trial only reported as
a letter and the type of placebo (or mode of
administration) is not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial described as double blind and placebo
controlled. However, trial only reported as
a letter and the type of placebo (or mode of
administration) is not clearly described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants included in analyses
Selective reporting (reporting bias) Low risk Trial gave impression that participants sur-
vived although this was not specifically
stated. We had no access to information
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Klotz 1989 (Continued)
about outcomes described in the original
protocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias High risk Trial only included 2 participants.
Overall assessment High risk High risk of bias.
Lacetti 2000
Methods Double-blind, single-centre, parallel-arm placebo-controlled RCT
Participants 54 participants with cirrhosis and acute hepatic encephalopathy (Grade III or IV). Pre-
cipitating factors are described (Table 4).
Mean age ± SD: flumazenil: 59.6 ± 6.0 years; placebo: 57.7 ± 5.4 years.
Proportion of men: 54%.
Aetiology of cirrhosis: hepatitis B/C 100%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 0%.
Interventions Intervention comparison: intravenous infusionflumazenil 0.4mg/mLat 10mL/minute
for 5 minutes versus placebo (saline)
Total dose of flumazenil: 2 mg.
Cointerventions: lactulose enemas; branch-chain amino acids.
Outcomes Outcomes included inmeta-analyses:mortality, hepatic encephalopathy (Table 1), and
serious adverse events (Table 6) assessed for maximum of 24 hours after intervention.
Neuropsychiatric assessment Baseline and post infusion:
• Clinical assessment of mental status (score not specified) assessed at baseline;
• Glasgow Coma Score (Table 2) assessed at baseline and every 30 minutes for the
first 6 hours and then every 6 hours for 24 hours post infusion.
Inclusion period (date) January 1997 to December 1997.
Country Italy.
Notes Included data: we included data on all participants in our analyses.
Notes about the design: investigators repeated the intervention once after 3 hours in
non-responders (no improvement in neurological status) or immediately if they detected
an improvement followed by a relapse. The report did not include information about
the number of participants who received a second infusion. In the results section of the
report the investigators stipulate that the second infusion was the same as the one first
received
Risk of bias
Bias Authors’ judgement Support for judgement
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Lacetti 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Double-blind administration of flumazenil
and placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel us-
ing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment using
placebo.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants were included in the analyses
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Li 2009
Methods Double-blind, single-centre, parallel-arm RCT.
Participants 72 participants with overt hepatic encephalopathy (Grade III or IV) associated with
cirrhosis (65%) or fulminant hepatic failure (35%). Diagnostic criteria for participants
with cirrhosis corresponded to acute hepatic encephalopathy
Mean age ± SD: flumazenil: 55.4 ± 6.6 years; placebo: 56.8 ± 7.9 years.
Proportion of men: 63%.
Aetiology of cirrhosis: not reported.
Proportion testing positive for benzodiazepines at baseline (Table 5): apparently not
performed (not specifically stated).
Interventions Intervention comparison: slow intravenous injection flumazenil 0.5 mg followed by
intravenous infusion of flumazenil 1 mg of over 30 minutes versus placebo (saline)
Total dose of flumazenil: 1.5 mg.
Cointerventions: lactulose enemas, L-ornithine L-aspartate
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed after a maximum of 2 weeks.
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Li 2009 (Continued)
Neuropsychiatric assessment Baseline and post infusion:
• Clinical scale (not specified) assessed at baseline;
• Glasgow Coma Score (Table 2) assessed at baseline and after 2 hours;
• Electroencephalography assessed at baseline and after 2 hours.
Inclusion period (date) May 2006 to July 2008.
Country China.
Notes Included data: the trial report did not provide separate information on participants with
cirrhosis and participants with acute liver failure. Therefore, we conducted a sensitivity
analysis excluding this trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Double-blind administration of flumazenil
and placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants included in the analyses
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in original pro-
tocol or information in trial registries
For-profit funding Unclear risk No information provided.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
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Pomier-Layrargues 1994
Methods Double-blind, single-centre, cross-over, placebo-controlled RCT
Cross-over design: investigators only crossed over participants who remained in Grade
IV coma, 24 hours after the first study period
Participants 21participantswith cirrhosis and acute hepatic encephalopathy (Grade IV). Precipitating
factors are described (Table 4).
Mean age ± SD: flumazenil: 52.7 ± 5.4 years; placebo: 57.4 ± 9.0 years.
Proportion of men: 81%.
Aetiology of cirrhosis: alcohol 62%; hepatitis B/C 5%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 4/21 (19%)
participants.
Interventions Intervention comparison: intravenous infusion flumazenil 2 mg over 5 minutes versus
placebo (saline)
Total dose of flumazenil: 2 mg.
Washout period: 24 hours.
Cointerventions: lactulose 30 mL 4 times daily.
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed after a maximum follow-up of 24 hours.
Neuropsychiatric assessment Baseline and post infusion:
• Modified Glasgow Coma Scale (Table 2) undertaken at baseline and every 15
minutes for up to 5.5 hours post infusion;
• Continuous electroencephalography (Table 3) 15 minutes before and 15 minutes
after the infusion.
Inclusion period (date) March 1988 to February 1992.
Country Canada.
Notes Included data: we only included data from the first treatment period in our analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers.
Allocation concealment (selection bias) Low risk Blinded administration of flumazenil or
placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
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Pomier-Layrargues 1994 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants included in analyses
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding High risk Technical assistance from Hoffmann-La
Roche Ltd., Canada and Nutley, NJ, USA
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
Van der Rijt 1995
Methods Double-blind, single-centre, cross-over, placebo-controlled RCT
Cross-over design: all participants (except 2 who underwent transplantation) received
flumazenil and placebo
Participants 18 participants with hepatic encephalopathy secondary to acute liver failure (28%) or
cirrhosis (82%), who had an arterial blood ammonia > 30 µmol/L, and an abnormal
electroencephalography despite at least 24 hours of treatment with a low protein diet
and lactulose alone or with neomycin. Precipitating factors are described (Table 4).
Mean age ± SD: whole group 48.56 ± 14.67 years.
Proportion of men: 39%.
Aetiology of cirrhosis: alcohol 38%; hepatitis B/C 15%.
Proportion testing positive for benzodiazepines at baseline (Table 5): 0%.
Interventions Intervention comparison 1:
First 9 participants: intravenous infusion flumazenil 0.1 mg/minute over 10 minutes; 4
hours later given a bolus injection flumazenil 0.5 mg followed by a continuous infusion
of flumazenil 0.25 mg/hour for 3 days versus infusion vehicle alone
Total dose of flumazenil: 19.5 mg.
Washout period: 24 hours.
Intervention comparison 2:
Second9participants: intravenous infusionof flumazenil 0.1mg/minute over 10minutes
versus infusion vehicle alone
Total dose of flumazenil: 19.5 mg.
Washout period 24 hours.
Cointerventions: protein restriction, lactulose alone or with neomycin.
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Van der Rijt 1995 (Continued)
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed after a maximum of 3 days.
Neuropsychiatric assessment First 9 participants: baseline and post infusion:
• Blood ammonia concentration assessed at baseline;
• Mental status assessed clinical scale (Table 2) at baseline and after 15 minutes and
then 24, 48, and 72 hours;
• Eectroencephalography, conventional and spectral grading (Table 3) recorded at
baseline and after 15 minutes and then 24, 48, and 72 hours.
Second 9 participants: baseline and post infusion:
• Blood ammonia concentration assessed at baseline;
• Mental status assessed clinical scale (Table 2) at baseline and after 15 minutes;
• Electroencephalography, conventional and spectral grading (Table 3) recorded at
baseline and after 15 minutes.
Inclusion period (date) February 1987 to February 1990.
Country The Netherlands.
Notes Included data: Two patients were withdrawn on day one of the study to undergo liver
transplantation thus only 16 people took part in the full cross-over study. The study
involved people with hepatic encephalopathy associated with cirrhosis and with acute
liver failure; the trial data were not provided separately for these two groups so no separate
analysis can be performed by aetiology of the hepatic encephalopathy. We only include
data from the first treatment period in our analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Used concealed drug containers.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and all partici-
pants were included in analyses
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
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Van der Rijt 1995 (Continued)
about outcomes described in original pro-
tocol or information in trial registries
For-profit funding High risk Support provided by Hoffmann-La Roche
B.V., Mijdrecht, The Netherlands
Other bias Unclear risk Investigators simplified the intervention
regimen after inclusion of the first 9 par-
ticipants as the second period of the 72-
hour infusion was too demanding for par-
ticipants. The effect that this has on bias
control was unclear
Overall assessment High risk High risk of bias.
Zhu 1998
Methods Double-blind, single-centre, parallel-arm, placebo-controlled RCT
Participants 25 participants with cirrhosis and overt hepatic encephalopathy (Grade II to IV). Pre-
cipitating factors are described (Table 4).
Mean age ± SD: flumazenil: 62.2 ± 2.7 years; placebo: 52.2 ± 3.3 years.
Proportion of men: 69%.
Aetiology of cirrhosis: alcohol 80%; hepatitis B/C 12%.
Proportion testing positive for benzodiazepines at baseline (Table 5): not conducted
(not specifically stated).
Interventions Intervention comparison: intravenous infusion flumazenil 1 mg over 5 minutes versus
placebo (saline)
Total dose of flumazenil: 1 mg.
Cointerventions: intravenous branched-chain amino acids.
Outcomes Outcomes included in meta-analyses: mortality, hepatic encephalopathy (Table 1),
and serious adverse events (Table 6) assessed for a maximum of 2 weeks (until death or
discharge)
Neuropsychiatric assessment Baseline and post infusion:
• Clinical assessment of hepatic encephalopathy (Table 2).
Inclusion period (date) April 1995 to March 1996.
Country China.
Notes Included data: all participants were included in the analyses.
Risk of bias
Bias Authors’ judgement Support for judgement
47Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhu 1998 (Continued)
Random sequence generation (selection
bias)
Low risk Randomnumbers with stratified block ran-
domisation.
Allocation concealment (selection bias) Low risk Administration of concealed drug contain-
ers with sealed, opaque, serially numbered
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing outcome data not described.
Selective reporting (reporting bias) Low risk Trial described clinically relevant out-
comes. We had no access to information
about outcomes described in the original
protocol or information in trial registries
For-profit funding High risk Roche supplied the flumazenil.
Other bias Low risk No other biases.
Overall assessment High risk High risk of bias.
RCT: randomised clinical trial; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bansky 1989 Prospective study including 14 participants with cirrhosis and overt hepatic encephalopathy. The investigators re-
ported an improvement inmental status in 71% of participants withinminutes of receiving intravenous flumazenil
lasting for 1 to 2 hours. Participants also received lactulose . Six participants died. The study was excluded as it
did not include a control group
Devictor 1995 Prospective study evaluating 7 children with fulminant hepatic failure awaiting emergency liver transplantation.
The investigators reported that flumazenil injection led to a transient improvement in mental status in 1 child
but had no effect on mental status in the remaining six. The study was excluded as none of the participants had
hepatic encephalopathy associated with cirrhosis and it did not include a control group
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(Continued)
Golubovic 1999 Prospective study including 10 participants with alcohol-related cirrhosis and overt hepatic encephalopathy clas-
sified as grade IV based on an assessment of mental status, electroencephalography, and visual evoked responses.
The investigators reported an improvement in mental status in 8/10 participants. Six participants died within 1
year. The study was excluded as it did not include a control group
Grimm 1988 Prospective study including 17 participants (2 children) with hepatic encephalopathy associated with acute liver
failure (9 participants) or cirrhosis (8 participants). Cointerventions included lactulose, branched-chain amino
acids, antibiotics, diuretics, histamine-receptor antagonists, human albumin, and fresh frozen plasma. Transient
improvement in the manifestations of hepatic encephalopathy was seen following flumazenil in 4 (44%) partic-
ipants with fulminant hepatic failure and 5 (63%) with cirrhosis. Mortality was not reported. This study was
excluded as it did not include a control group
Jia 1999 Open, single-centre, non-randomised study which is included in the sensitivity analyses of serious adverse events.
The study involved 22 participants with cirrhosis and overt hepatic encephalopathy (Grades I-III using West
Haven criteria) recruited between April 1996 and September 1997
Intervention comparison: 12 participants received an intravenous bolus of flumazenil 0.5 mg followed by an
intravenous infusion of flumazenil in a dose of 1.0 mg over 4 hours for an unspecified period of time. The
remaining 10 participants received Xing-Nao-Jing, a traditional Chinese medicine also given as an intravenous
infusion
Total dose of flumazenil: 1.5 mg.
Outcomes: The study report stated that 2 participants in the flumazenil group died of liver failure but the time of
death in relation to the intervention was not specified and study did not specifically state if there were any deaths
in control group. The article was published in Chinese but a translation was available. The study was excluded as
it did not contain a control group
Kapczinski 1995 Double-blind, cross-over, placebo-controlled, single-centre randomised clinical trial including 20 liver transplant
candidates with cirrhosis. The trial is included in the sensitivity analyses of serious adverse events. The main
objective of trial was to evaluate the differential effects of flumazenil on cognitive function and anxiety in people
with alcohol-related (10 participants) or non-alcohol-related (10 participants) cirrhosis. None of the included
participants had evidence of overt hepatic encephalopathy. The investigators evaluated a range of psychometric
tests and reported the results as groupmean values. No information was provided about the number of participants
with abnormal test results
Proportion of men: 60%.
Mean ± SD age: alcohol-related cirrhosis: 47.7 ± 10.5 years; non-alcoholic cirrhosis: 48.4 ± 11.7 years
Proportion testing positive for benzodiazepines at baseline: not tested
Intervention: intravenous infusion flumazenil 0.1mg/minute for 10minutes then 0.05mg/minute for 20minutes
versus placebo (saline)
Total dose of flumazenil: 2 mg.
Washout period: 60 minutes.
Outcomes: The investigators reported changes in psychometric tests for participants with alcohol-related or
non-alcohol-related cirrhosis without providing an overall estimate of numbers with (or without) improved
manifestations. The trial did not report any deaths or serious adverse events
The study was excluded because none of the participants had hepatic encephalopathy
Marsepoil 1990 Open, single-centre, prospective, non-randomised study included in the sensitivity analyses of serious adverse
events at 48 hours. The study involved 25 participants with alcohol-related cirrhosis and acute hepatic en-
cephalopathy, 13 of whom received flumazenil. The proportion of men and the mean age of participants was not
reported
Proportion testing positive for benzodiazepines at baseline: not mentioned
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(Continued)
Intervention: intravenous bolus of flumazenil 0.2 mg every ten minutes until improvement in clinical status up
to a maximum total dose of 2 mg followed by a continuous maintenance infusion of 0.3 mg. per hour for 48
hours
Total dose of flumazenil: maximum 16.4 mg.
Outcomes: .The Investigators reported that the mortality rates were similar in the flumazenil and control groups,
but did not provide information on the number of participants who died. Published in French but a translation
was available.The study was excluded as it was not randomised
Ozyilkan 1997 Prospective study evaluating the effect of 30-minute, incremental intravenous boluses of flumazenil in 11 partici-
pants with cirrhosis (6 stage 0,4 stage one, one stage 2 hepatic encephalopathy) in whom baseline somatosensory
evoked potentials were abnormal. Four patients (36%) showed a clear improvement in evoked potentials with
flumazenil. Mortality was not described. The study was excluded as it did not include a control group
Wu 2001 Randomised clinical trial comparing intravenous flumazenil plus lactulose enemas versus flumazenil alone. A
total of 20 participants (18 men) with cirrhosis and hepatic encephalopathy were included. The maximum
dose of flumazenil was 9 mg. The dose was adjusted based on the clinical effect. Investigators assessed hepatic
encephalopathy based on Conn Criteria and defined an improvement from Grade IV to I within 6 hours as
clinically significant. None of the included participants died and all 12 in the flumazenil plus lactulose group and
all 8 in the flumazenil group showed improved manifestations of hepatic encephalopathy. The study was excluded
as there was no placebo arm
.
Characteristics of ongoing studies [ordered by study ID]
Yale 2014
Trial name or title Treatment of Hepatic Encephalopathy with Flumazenil and Change in Cortical Gamma Aminobutyric Acid
Levels in MRS [magnetic resonance spectroscopy]
Methods Randomised clinical trial.
Participants Participants with non-alcoholic cirrhosis and hepatic encephalopathy
Interventions Flumazenil and placebo.
Outcomes Recovery from hepatic encephalopathy and change in cortical gamma aminobutyric acid levels
Starting date November 2014.
Contact information Deanna Martin, deanna.martin@yale.edu and Amanda Brennan amanda.brennan@yale.edu.
Notes Estimated completion date: June 2017.
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D A T A A N D A N A L Y S E S
Comparison 1. Flumazenil versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 11 842 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.48, 1.16]
1.1 Overt hepatic
encephalopathy
10 822 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.48, 1.16]
1.2 Minimal hepatic
encephalopathy
2 20 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 All-cause mortality and bias
control
12 844 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.48, 1.16]
2.1 Low risk of bias 1 527 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.37, 1.53]
2.2 High risk of bias 11 317 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.43, 1.31]
3 All-cause mortality and trial
design
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Cross-over 6 592 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.35, 1.34]
3.2 Parallel-arm 6 252 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.45, 1.44]
4 All-cause mortality and duration
of follow-up
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 ≤ 1 day 5 176 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.38, 1.87]
4.2 > 1 day 6 666 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.42, 1.21]
5 Hepatic encephalopathy 9 824 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.71, 0.80]
5.1 Overt hepatic
encephalopathy
9 814 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.67, 0.80]
5.2 Minimal hepatic
encephalopathy
1 10 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.41, 1.39]
6 Hepatic encephalopathy and
bias control
9 824 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.71, 0.80]
6.1 Low risk of bias 1 527 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.72, 0.84]
6.2 High risk of bias 8 297 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.61, 0.78]
7 Hepatic encephalopathy and
trial design
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Cross-over 4 584 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.72, 0.83]
7.2 Parallel-arm 5 240 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.59, 0.79]
8 Hepatic encephalopathy and
duration of follow-up
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 ≤ 1 day 4 164 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.60, 0.83]
8.2 > 1 day 5 660 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.62, 0.84]
9 Hepatic encephalopathy and
acute liver failure
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Cirrhosis 7 734 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.71, 0.82]
9.2 Acute liver failure or
cirrhosis
2 90 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.47, 0.80]
10 Number Connection Test 1 Mean Difference (IV, Random, 95% CI) Totals not selected
11 All-cause mortality and acute
liver failure
11 842 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.48, 1.16]
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11.1 Participants with
cirrhosis
9 752 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.45, 1.14]
11.2 Participants with
cirrhosis or acute liver failure
2 90 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.31, 3.62]
Analysis 1.1. Comparison 1 Flumazenil versus placebo, Outcome 1 All-cause mortality.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 1 All-cause mortality
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overt hepatic encephalopathy
Barbaro 1998 13/265 17/262 39.0 % 0.76 [ 0.37, 1.53 ]
Cadranel 1995 1/9 2/5 4.2 % 0.28 [ 0.03, 2.35 ]
Dursun 2003 0/16 0/14 Not estimable
Gyr 1996 4/28 5/21 13.6 % 0.60 [ 0.18, 1.97 ]
Hermant 1991 0/6 0/6 Not estimable
Lacetti 2000 6/28 5/26 17.1 % 1.11 [ 0.39, 3.22 ]
Li 2009 5/39 4/33 12.7 % 1.06 [ 0.31, 3.62 ]
Pomier-Layrargues 1994 0/11 0/10 Not estimable
Van der Rijt 1995 0/9 0/9 Not estimable
Zhu 1998 3/13 5/12 13.4 % 0.55 [ 0.17, 1.83 ]
Subtotal (95% CI) 424 398 100.0 % 0.75 [ 0.48, 1.16 ]
Total events: 32 (Flumazenil), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Minimal hepatic encephalopathy
Dursun 2003 0/4 0/6 Not estimable
Gooday 1995 0/5 0/5 Not estimable
Subtotal (95% CI) 9 11 Not estimable
Total events: 0 (Flumazenil), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 433 409 100.0 % 0.75 [ 0.48, 1.16 ]
Total events: 32 (Flumazenil), 38 (Placebo)
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
Analysis 1.2. Comparison 1 Flumazenil versus placebo, Outcome 2 All-cause mortality and bias control.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 2 All-cause mortality and bias control
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
Barbaro 1998 13/265 17/262 39.0 % 0.76 [ 0.37, 1.53 ]
Subtotal (95% CI) 265 262 39.0 % 0.76 [ 0.37, 1.53 ]
Total events: 13 (Flumazenil), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 High risk of bias
Cadranel 1995 1/9 2/5 4.2 % 0.28 [ 0.03, 2.35 ]
Dursun 2003 0/20 0/20 Not estimable
Gooday 1995 0/5 0/5 Not estimable
Gyr 1996 4/28 5/21 13.6 % 0.60 [ 0.18, 1.97 ]
Hermant 1991 0/6 0/6 Not estimable
Klotz 1989 0/1 0/1 Not estimable
Lacetti 2000 6/28 5/26 17.1 % 1.11 [ 0.39, 3.22 ]
Li 2009 5/39 4/33 12.7 % 1.06 [ 0.31, 3.62 ]
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pomier-Layrargues 1994 0/11 0/10 Not estimable
Van der Rijt 1995 0/9 0/9 Not estimable
Zhu 1998 3/13 5/12 13.4 % 0.55 [ 0.17, 1.83 ]
Subtotal (95% CI) 169 148 61.0 % 0.75 [ 0.43, 1.31 ]
Total events: 19 (Flumazenil), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 434 410 100.0 % 0.75 [ 0.48, 1.16 ]
Total events: 32 (Flumazenil), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
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Analysis 1.3. Comparison 1 Flumazenil versus placebo, Outcome 3 All-cause mortality and trial design.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 3 All-cause mortality and trial design
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cross-over
Barbaro 1998 13/265 17/262 90.3 % 0.76 [ 0.37, 1.53 ]
Cadranel 1995 1/9 2/5 9.7 % 0.28 [ 0.03, 2.35 ]
Gooday 1995 0/5 0/5 Not estimable
Klotz 1989 0/1 0/1 Not estimable
Pomier-Layrargues 1994 0/11 0/10 Not estimable
Van der Rijt 1995 0/9 0/9 Not estimable
Subtotal (95% CI) 300 292 100.0 % 0.69 [ 0.35, 1.34 ]
Total events: 14 (Flumazenil), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 Parallel-arm
Dursun 2003 0/20 0/20 Not estimable
Gyr 1996 4/28 5/21 24.0 % 0.60 [ 0.18, 1.97 ]
Hermant 1991 0/6 0/6 Not estimable
Lacetti 2000 6/28 5/26 30.1 % 1.11 [ 0.39, 3.22 ]
Li 2009 5/39 4/33 22.3 % 1.06 [ 0.31, 3.62 ]
Zhu 1998 3/13 5/12 23.6 % 0.55 [ 0.17, 1.83 ]
Subtotal (95% CI) 134 118 100.0 % 0.81 [ 0.45, 1.44 ]
Total events: 18 (Flumazenil), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
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Analysis 1.4. Comparison 1 Flumazenil versus placebo, Outcome 4 All-cause mortality and duration of
follow-up.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 4 All-cause mortality and duration of follow-up
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≤ 1 day
Dursun 2003 0/20 0/20 Not estimable
Gyr 1996 4/28 5/21 44.4 % 0.60 [ 0.18, 1.97 ]
Hermant 1991 0/6 0/6 Not estimable
Lacetti 2000 6/28 5/26 55.6 % 1.11 [ 0.39, 3.22 ]
Pomier-Layrargues 1994 0/11 0/10 Not estimable
Subtotal (95% CI) 93 83 100.0 % 0.85 [ 0.38, 1.87 ]
Total events: 10 (Flumazenil), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 > 1 day
Barbaro 1998 13/265 17/262 56.3 % 0.76 [ 0.37, 1.53 ]
Cadranel 1995 1/9 2/5 6.1 % 0.28 [ 0.03, 2.35 ]
Gooday 1995 0/5 0/5 Not estimable
Li 2009 5/39 4/33 18.3 % 1.06 [ 0.31, 3.62 ]
Van der Rijt 1995 0/9 0/9 Not estimable
Zhu 1998 3/13 5/12 19.3 % 0.55 [ 0.17, 1.83 ]
Subtotal (95% CI) 340 326 100.0 % 0.71 [ 0.42, 1.21 ]
Total events: 22 (Flumazenil), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.34, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
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Analysis 1.5. Comparison 1 Flumazenil versus placebo, Outcome 5 Hepatic encephalopathy.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 5 Hepatic encephalopathy
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overt hepatic encephalopathy
Barbaro 1998 199/265 253/262 74.9 % 0.78 [ 0.72, 0.84 ]
Cadranel 1995 4/10 8/8 0.8 % 0.43 [ 0.21, 0.90 ]
Dursun 2003 9/16 14/14 2.2 % 0.58 [ 0.38, 0.89 ]
Gyr 1996 21/28 21/21 8.1 % 0.76 [ 0.61, 0.95 ]
Lacetti 2000 6/28 12/26 0.6 % 0.46 [ 0.20, 1.06 ]
Li 2009 22/39 31/33 4.8 % 0.60 [ 0.45, 0.80 ]
Pomier-Layrargues 1994 8/11 10/10 2.7 % 0.74 [ 0.50, 1.09 ]
Van der Rijt 1995 5/9 7/9 0.9 % 0.71 [ 0.36, 1.41 ]
Zhu 1998 10/13 12/12 3.9 % 0.78 [ 0.57, 1.08 ]
Subtotal (95% CI) 419 395 98.9 % 0.73 [ 0.67, 0.80 ]
Total events: 284 (Flumazenil), 368 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 9.02, df = 8 (P = 0.34); I2 =11%
Test for overall effect: Z = 6.60 (P < 0.00001)
2 Minimal hepatic encephalopathy
Dursun 2003 3/4 6/6 1.1 % 0.75 [ 0.41, 1.39 ]
Subtotal (95% CI) 4 6 1.1 % 0.75 [ 0.41, 1.39 ]
Total events: 3 (Flumazenil), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 423 401 100.0 % 0.75 [ 0.71, 0.80 ]
Total events: 287 (Flumazenil), 374 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 9.01, df = 9 (P = 0.44); I2 =0%
Test for overall effect: Z = 8.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.02 0.1 1 10 50
Favours flumazenil Favours placebo
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Analysis 1.6. Comparison 1 Flumazenil versus placebo, Outcome 6 Hepatic encephalopathy and bias
control.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 6 Hepatic encephalopathy and bias control
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
Barbaro 1998 199/265 253/262 74.9 % 0.78 [ 0.72, 0.84 ]
Subtotal (95% CI) 265 262 74.9 % 0.78 [ 0.72, 0.84 ]
Total events: 199 (Flumazenil), 253 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 6.75 (P < 0.00001)
2 High risk of bias
Cadranel 1995 4/10 8/8 0.8 % 0.43 [ 0.21, 0.90 ]
Dursun 2003 3/4 6/6 1.1 % 0.75 [ 0.41, 1.39 ]
Dursun 2003 9/16 14/14 2.2 % 0.58 [ 0.38, 0.89 ]
Gyr 1996 21/28 21/21 8.1 % 0.76 [ 0.61, 0.95 ]
Lacetti 2000 6/28 12/26 0.6 % 0.46 [ 0.20, 1.06 ]
Li 2009 22/39 31/33 4.8 % 0.60 [ 0.45, 0.80 ]
Pomier-Layrargues 1994 8/11 10/10 2.7 % 0.74 [ 0.50, 1.09 ]
Van der Rijt 1995 5/9 7/9 0.9 % 0.71 [ 0.36, 1.41 ]
Zhu 1998 10/13 12/12 3.9 % 0.78 [ 0.57, 1.08 ]
Subtotal (95% CI) 158 139 25.1 % 0.69 [ 0.61, 0.78 ]
Total events: 88 (Flumazenil), 121 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.48, df = 8 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.77 (P < 0.00001)
Total (95% CI) 423 401 100.0 % 0.75 [ 0.71, 0.80 ]
Total events: 287 (Flumazenil), 374 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 9.01, df = 9 (P = 0.44); I2 =0%
Test for overall effect: Z = 8.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.69, df = 1 (P = 0.10), I2 =63%
0.02 0.1 1 10 50
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Analysis 1.7. Comparison 1 Flumazenil versus placebo, Outcome 7 Hepatic encephalopathy and trial design.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 7 Hepatic encephalopathy and trial design
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cross-over
Barbaro 1998 199/265 253/262 94.6 % 0.78 [ 0.72, 0.84 ]
Cadranel 1995 4/10 8/8 1.0 % 0.43 [ 0.21, 0.90 ]
Pomier-Layrargues 1994 8/11 10/10 3.4 % 0.74 [ 0.50, 1.09 ]
Van der Rijt 1995 5/9 7/9 1.1 % 0.71 [ 0.36, 1.41 ]
Subtotal (95% CI) 295 289 100.0 % 0.77 [ 0.72, 0.83 ]
Total events: 216 (Flumazenil), 278 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.64, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 7.17 (P < 0.00001)
2 Parallel-arm
Dursun 2003 12/20 20/20 15.9 % 0.61 [ 0.43, 0.87 ]
Gyr 1996 21/28 21/21 37.6 % 0.76 [ 0.61, 0.95 ]
Lacetti 2000 6/28 12/26 3.2 % 0.46 [ 0.20, 1.06 ]
Li 2009 22/39 31/33 23.8 % 0.60 [ 0.45, 0.80 ]
Zhu 1998 10/13 12/12 19.6 % 0.78 [ 0.57, 1.08 ]
Subtotal (95% CI) 128 112 100.0 % 0.69 [ 0.59, 0.79 ]
Total events: 71 (Flumazenil), 96 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.28, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 5.02 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.98, df = 1 (P = 0.16), I2 =49%
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Analysis 1.8. Comparison 1 Flumazenil versus placebo, Outcome 8 Hepatic encephalopathy and duration of
follow-up.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 8 Hepatic encephalopathy and duration of follow-up
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≤ 1 day
Dursun 2003 12/20 20/20 21.6 % 0.61 [ 0.43, 0.87 ]
Gyr 1996 21/28 21/21 55.5 % 0.76 [ 0.61, 0.95 ]
Lacetti 2000 6/28 12/26 4.1 % 0.46 [ 0.20, 1.06 ]
Pomier-Layrargues 1994 8/11 10/10 18.8 % 0.74 [ 0.50, 1.09 ]
Subtotal (95% CI) 87 77 100.0 % 0.71 [ 0.60, 0.83 ]
Total events: 47 (Flumazenil), 63 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.08 (P = 0.000044)
2 > 1 day
Barbaro 1998 199/265 253/262 56.8 % 0.78 [ 0.72, 0.84 ]
Cadranel 1995 4/10 8/8 3.9 % 0.43 [ 0.21, 0.90 ]
Li 2009 22/39 31/33 18.8 % 0.60 [ 0.45, 0.80 ]
Van der Rijt 1995 5/9 7/9 4.4 % 0.71 [ 0.36, 1.41 ]
Zhu 1998 10/13 12/12 16.1 % 0.78 [ 0.57, 1.08 ]
Subtotal (95% CI) 336 324 100.0 % 0.72 [ 0.62, 0.84 ]
Total events: 240 (Flumazenil), 311 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.58, df = 4 (P = 0.23); I2 =28%
Test for overall effect: Z = 4.31 (P = 0.000016)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 1.9. Comparison 1 Flumazenil versus placebo, Outcome 9 Hepatic encephalopathy and acute liver
failure.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 9 Hepatic encephalopathy and acute liver failure
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cirrhosis
Barbaro 1998 199/265 253/262 78.1 % 0.78 [ 0.72, 0.84 ]
Cadranel 1995 4/10 8/8 0.9 % 0.43 [ 0.21, 0.90 ]
Dursun 2003 12/20 20/20 3.6 % 0.61 [ 0.43, 0.87 ]
Gyr 1996 21/28 21/21 9.1 % 0.76 [ 0.61, 0.95 ]
Lacetti 2000 6/28 12/26 0.7 % 0.46 [ 0.20, 1.06 ]
Pomier-Layrargues 1994 8/11 10/10 3.1 % 0.74 [ 0.50, 1.09 ]
Zhu 1998 10/13 12/12 4.5 % 0.78 [ 0.57, 1.08 ]
Subtotal (95% CI) 375 359 100.0 % 0.76 [ 0.71, 0.82 ]
Total events: 260 (Flumazenil), 336 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.05, df = 6 (P = 0.42); I2 =1%
Test for overall effect: Z = 7.83 (P < 0.00001)
2 Acute liver failure or cirrhosis
Li 2009 22/39 31/33 84.7 % 0.60 [ 0.45, 0.80 ]
Van der Rijt 1995 5/9 7/9 15.3 % 0.71 [ 0.36, 1.41 ]
Subtotal (95% CI) 48 42 100.0 % 0.62 [ 0.47, 0.80 ]
Total events: 27 (Flumazenil), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Chi2 = 2.27, df = 1 (P = 0.13), I2 =56%
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Analysis 1.10. Comparison 1 Flumazenil versus placebo, Outcome 10 Number Connection Test.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 10 Number Connection Test
Study or subgroup Flumazenil Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[seconds] N Mean(SD)[seconds] IV,Random,95% CI IV,Random,95% CI
Dursun 2003 20 86.56 (47.37) 20 90.35 (44.05) -3.79 [ -32.14, 24.56 ]
-50 -25 0 25 50
Favours flumazenil Favours placebo
Analysis 1.11. Comparison 1 Flumazenil versus placebo, Outcome 11 All-cause mortality and acute liver
failure.
Review: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Comparison: 1 Flumazenil versus placebo
Outcome: 11 All-cause mortality and acute liver failure
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Participants with cirrhosis
Barbaro 1998 13/265 17/262 39.0 % 0.76 [ 0.37, 1.53 ]
Cadranel 1995 1/9 2/5 4.2 % 0.28 [ 0.03, 2.35 ]
Dursun 2003 0/20 0/20 Not estimable
Gooday 1995 0/5 0/5 Not estimable
Gyr 1996 4/28 5/21 13.6 % 0.60 [ 0.18, 1.97 ]
Hermant 1991 0/6 0/6 Not estimable
Lacetti 2000 6/28 5/26 17.1 % 1.11 [ 0.39, 3.22 ]
Pomier-Layrargues 1994 0/11 0/10 Not estimable
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Flumazenil Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Zhu 1998 3/13 5/12 13.4 % 0.55 [ 0.17, 1.83 ]
Subtotal (95% CI) 385 367 87.3 % 0.71 [ 0.45, 1.14 ]
Total events: 27 (Flumazenil), 34 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Participants with cirrhosis or acute liver failure
Li 2009 5/39 4/33 12.7 % 1.06 [ 0.31, 3.62 ]
Van der Rijt 1995 0/9 0/9 Not estimable
Subtotal (95% CI) 48 42 12.7 % 1.06 [ 0.31, 3.62 ]
Total events: 5 (Flumazenil), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 433 409 100.0 % 0.75 [ 0.48, 1.16 ]
Total events: 32 (Flumazenil), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
0.01 0.1 1 10 100
Favours flumazenil Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Definition of improved manifestations of hepatic encephalopathy
Trial Type of hepatic encephalopathy Neuropsychiatric assessment Definition of overall improve-
ment
Amodio 1997 Minimal Number Connection Test and
Brainstem Auditory Evoked Re-
sponse
Investigators did not define or as-
sess the number of participants
with an overall improvement
Barbaro 1998 Overt Mental status assessed using a
clinical scale (Table 2), Modified
Glasgow Coma Scale (Table 2)
, and electroencephalography (
Table 3).
Improvement in clinical scores or
electroencephalography.
Cadranel 1995 Overt Mental status assessed using a
clinical scale (Table 2), and elec-
troencephalography (Table 3).
Improvement in clinical score or
electroencephalography.
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Table 1. Definition of improved manifestations of hepatic encephalopathy (Continued)
Dursun 2003 Minimal or overt Mental status assessed using a
clinical scale (Table 2), Number
Connection Test results, and elec-
troencephalography (Table 3).
Improvement based on the clin-
ical score and Number Connec-
tion Test results
Giger-Mateeva 1999 Minimal Number Connection Test and
brainstem auditory evoked re-
sponse
Not defined. The investigators in-
cluded a post-hoc subjective as-
sessment of alertness
Gooday 1995 Minimal Simple and complex reaction
time, verbal memory, psychomo-
tor speed, short-term and work-
ing memory
Improvement in psychomotor
speed evaluated using change in
reaction time; Investigators did
not define or assess the number of
participants with overall improve-
ment.
Gyr 1996 Overt Mental status (Table 2), and elec-
troencephalography (Table 3).
Clinically relevant improvement
defined as a 2-point improvement
in clinical score at any time during
treatment compared with base-
line. The investigators also re-
ported improvement defined us-
ing the clinical scale score (mean
for all individual observations)
Hermant 1991 Overt Glasgow Coma Scale (Table 2),
and electroencephalography.
A 2-point improvement in the
Glasgow Coma Score and elec-
troencephalography
Klotz 1989 Overt Clinical assessment (score not de-
scribed).
Improvement in clinical status
Lacetti 2000 Overt Mental status (scale not specified)
and Glasgow Coma Scale (Table
2).
Investigators originally classified
participants as Grade III to IV
coma. Method of assessment not
stipulated. The trial report de-
fined ’clinically relevant improve-
ment’ as primary outcome de-
fined as a 3-point improvement in
Glasgow Coma Score
Li 2009 Overt Glasgow Coma Scale (Table 2),
and electroencephalography
Improvement in the Glasgow
Coma Score of ≥ 3 points.
Pomier-Layrargues 1994 Overt Modified Glasgow Coma Score
(Table 2), and electroencephalog-
raphy.
Improvement in ≥ 2 items on
modified Glasgow Coma Score
within 1 hour after the end of
treatment
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Table 1. Definition of improved manifestations of hepatic encephalopathy (Continued)
Van der Rijt 1995 Overt Clinical scale (Table 2). A ≥ 1 -point decrease in severity
of hepatic encephalopathy.
Zhu 1998 Overt Clinical scale (Table 2). Overall improvement in hepatic
encephalopathy based on clinical
grade
RCT: randomised clinical trial.
Table 2. Neuropsychiatric assessment scales
Scale (Grippon 1988) used in Cadranel 1995; Barbaro 1998.
I Euphoria or depression,mild confusion, slowness, disorder in sleep
rhythm
II Drowsiness, inappropriate behaviour, accentuation of stage I
III Stupor; participant sleeps most of the time, but is rousable; inco-
herent speech; marked confusion
IVa Coma, co-ordinated response to painful stimuli.
IVb Coma, hyperextension, and pronosupination after painful stimuli
IVc Coma, no response to painful stimuli.
V Clinical decerebration.
Scale (Fitz 1998) used in Dursun 2003.
Subclinical Normal examination with subtle changes in psychometric or
Number Connection Tests
I Impaired attention, irritability, depression, or personality changes
II Drowsiness, behavioural changes, sleep disorders, and poor mem-
ory
III Confusion, disorientation, somnolence, and amnesia.
Scale (Jones 1988) used in Gyr 1996.
- Clinical assessment criteria consisted of the anamnestic criterion:
disorders of sleep pattern (insomnia, hypersomnia, inversion of
sleep rhythm) in combination with assessment of the level of con-
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Table 2. Neuropsychiatric assessment scales (Continued)
sciousness (1 to 4 as described below). Score items weighted so
major disturbances of consciousness (portal systemic encephalopa-
thy stage III and IV) were associated with scores of ≥ 11. Portal
systemic encephalopathy stage II defined as scores of 5 to 10 and
stage I of 3 to 4
1 Light disturbance of consciousness if ≥ 1 of following symptoms
were present: drowsiness (tendency to fall asleep but wake up spon-
taneously or in response to normal voice or light), intermittent or
permanent disorientation, retardation of ability to performmental
tasks (serial subtractions of sevens), mood disorder, inappropriate
behaviour
2 Somnolence (arousable to physical stimuli such as mild prodding
or shaking only)
3 Stupor (localised motor response to pain).
4 Coma (unarousability, no or unlocalisedmotor reactions to painful
stimuli)
Scale (no reference provided in paper) used in Van der Rijt 1995.
1 Presence of≥ 2 of following abnormalities: inverted sleep pattern,
disturbed memory, impaired calculation (serial sevens), slowness
of speech, or flapping tremor
2 Presence of ≥ 2 of following: lethargy, time disorientation, or
flapping tremor
3 Presence of ≥ 2 of following: a state in which person had to be
stimulated repetitively to open his/her eyes or execute commands,
disorientation in terms of place and disorientation with respect to
person
4 Coma.
Scale (Conn 1977) used in Zhu 1998.
1 Trivial lack of awareness, euphoria or anxiety, shortened attention
span, impaired performance of addition or subtraction
2 Lethargy or apathy, minimal disorientation for time or place, sub-
tle personality change, inappropriate behaviour
3 Somnolence to semistupor, but responsive to verbal stimuli; con-
fusion; gross disorientation
4 Coma.
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Table 2. Neuropsychiatric assessment scales (Continued)
Glasgow Coma Scale (CGS) (Teasdale 1974) used in Hermant 1991; Lacetti 2000; Dursun 2003; Li 2009.
Scores Eye opening (E):
• 4 = spontaneous;
• 3 = to voice;
• 2 = to pain;
• 1 = none.
Verbal response (V):
• 5 = normal conversation;
• 4 = disoriented conversation;
• 3 = words, but not coherent;
• 2 = no words, only sounds;
• 1 = none.
Motor response (M):
• 6 = normal;
• 5 = localised to pain;
• 4 = withdraws to pain;
• 3 = decorticate posture (an abnormal posture that can
include rigidity, clenched fists, legs held straight out, and arms
bent inwards towards the body with wrists and fingers bend and
held on chest);
• 2 = decerebrate (an abnormal posture that can include
rigidity, arms and legs held straight out, toes pointed downwards,
head and neck arched backwards);
• 1 = none.
Grading • Severe: GCS 3-8 (minimum score 3).
• Moderate: GCS 9-12.
• Mild: GCS 13-15.
Modified Glasgow Coma Scale (Pappas 1983) used in Pomier-Layrargues 1994; Barbaro 1998.
Scores 1. Verbal ability;
2. Eye-opening;
3. Pupillary light reflex;
4. Corneal reflex;
5. Spontaneous eye movements;
6. Oculocephalic reflex;
7. Motor response; and
8. Pattern of respiration.
Table 3. Assessment of electroencephalography changes
Electroencephalography grading/Fischer classification (Nusinovici 1977 and Spehlman 1991) used in Hermant 1991; Pomier-
Layrargues 1994; Cadranel 1995; Barbaro 1998.
I Irregular background activity (theta and alpha).
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Table 3. Assessment of electroencephalography changes (Continued)
II Continuous theta activity, bursts of delta waves.
III Prevalent delta activity; polyphasic transients sharp and slow wave
complexes
IVa Continuous delta activity; abundant sharp and slow wave com-
plexes; electroencephalography reactivity present
IVb Slower activity (delta and some polyphasic transients); electroen-
cephalography reactivity = 0
IVc Discontinuous activity with silent periods.
V Flat.
Electroencephalography grading (Parsons-Smith 1957) used in Dursun 2003.
A Generalised suppression of alpha rhythm and its frequent replace-
ment by faster potentials in all leads. The tracings in this grade
are generally flat and featureless
B Alpha rhythm very unstable and disturbed by random waves at
5-7 per second over both hemispheres. Rhythms most often seen
over temporal lobes. In many cases with underlying fast activity
C Alpha rhythm still seen, but disturbed over both hemispheres by
medium-voltage 5-6 per second waves. These occur in runs, are
not paroxysmal, and do not usually block to eye opening although
blocking may occur. Rhythms are particularly well seen over tem-
poral and frontal lobes
D 5-6 per second rhythms seen in grade C are now constant in all
areas and replace all other cortical activity recorded on electroen-
cephalogram. Appearance of this abnormality in a patient present-
ing with only slight neuropsychiatric symptoms is very striking
E 5 to 6 per second rhythms replaced by frontally preponderant bi-
lateral synchronous 2 per second rhythms, which spread back-
wards over hemispheres. At times, 6 per second rhythms might
reappear, but special features of records are occurrence of these
diencephalic discharges
Electroencephalography grading (Kennedy 1973) used in Gyr 1996.
0 8 to 12 per second basic rhythm, mean dominant frequency > 8
per second, % theta < 20
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Table 3. Assessment of electroencephalography changes (Continued)
1 Sudden shifts between normal alpha frequency (around 9 or 10
per second) and slow substitutes (6-8 per second);mean dominant
frequency > 7 per second, % theta > 35
2 Diffuse slow activity posterior alpha rhythm seen occasionally,
mean dominant frequency 5 to 7 per second, % theta > 60
3 Dominant slow activity in all areas, mean dominant frequency 3
to 5 per second, % delta 70
4 Bilaterally synchronous, 2-3 per second waves, predominating
over frontal lobes and spreading backwards to occipital lobes; oc-
casional short-lived appearance of faster rhythms (5 or 6 per sec-
ond) or voltage depression, mean dominant frequency < 3 per
second, % delta 70
Electroencephalography grading (Markand 1984) used in Van der Rijt 1995.
0 Background activity consisting of alpha rhythm.
1 Alpha rhythm with some scattered theta waves.
2 Background activity of theta activity intermixed with some delta
and alpha frequencies
3 Background of delta polymorphic activity of high amplitude with
spontaneous variability
4 Delta activity of relatively small amplitude.
Table 4. Precipitating factors
Trial Participants
(n)
Precipitating factors (n)
Barbaro 1998 527 Gastrointestinal bleeding (352), surgery (95), sepsis (45), dehydration (6), unknown
(29)
Cadranel 1995 14 Gastrointestinal bleeding (4), sepsis (7), alcoholic hepatitis (3), portal vein thrombosis
(1), viral hepatitis (1), unknown (2)
Lacetti 2000 54 Gastrointestinal bleeding (31), sepsis (7), drugs (11), surgery (1)
Pomier-Layrargues 1994 21 Gastrointestinal bleeding (7), sepsis (2), dehydration (1), surgery (2), none (9), por-
tacaval shunting (4)
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Table 4. Precipitating factors (Continued)
Van der Rijt 1995 18 Hepatitis (5), acute exacerbation in cirrhosis (2), partial hepatectomy (1)
Zhu 1998 25 Gastrointestinal bleeding (13), protein overload (6), infection (2), wounds (1), un-
known (3)
n: number of participants.
Table 5. Baseline screening for benzodiazepines in trial participants
Trial Re-
quired period free
of benzodiazepines
before inclusion
Baseline
screening for ben-
zodiazepines
Screening method
and detection level
Negative testing at
baseline an inclu-
sion criterion
Proportion testing
positive for benzo-
diazepines at base-
line
Amodio 1997 2 weeks Yes • Blood
• Emit-dau
technique, Dupont
• Detection
limit 0.3 µg/mL
diazepam
No 0%
Barbaro 1998 4 days Yes • Blood
• Thin-layer
chromatography:
• Detection
limit > 11 mg/L
No 1.9%
Cadranel 1995 Not reported Yes • Blood and
urine
• Thin-layer
chromatography:
• Detection
limit > 11 mg/L
No 21.4%
Dursun 2003 3 days No Not reported Not reported Not reported
Giger-Mateeva
1999
3 months Yes • Urine
• Abbott TDx/
TDxFLx
immunoassay
• Detection
limit < 200 ng/mL
No 0%
Gooday 1995 1 month No Not reported Not reported Not reported
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Table 5. Baseline screening for benzodiazepines in trial participants (Continued)
Gyr 1996 Yes, but length not
specified
Yes • Blood and
urine
• Abbott TDx
immunoassay
• Detection
limits: blood 10 ng/
mL 100 ng/mL,
urine < 200 ng/mL
Post-hoc analysis
• High-pressure
liquid
chromatography
• Detection
limits: blood < 50
ng/mL, urine 10
ng/mL to 100 ng/
mL
No 8.2% on screening
tests
Flumazenil 11%;
placebo 5%
12/49 samples for
more sensitive test-
ing lost
Hermant 1991 Not reported Yes Not reported Yes 0%
Klotz 1989 Not reported No Not reported Not reported Not reported
Lacetti 2000 2 weeks Yes • Urine
• Roche KIMS
immuno-enzymatic
assay
• Detection
limit: not specified
Post-hoc analysis
• High-pressure
liquid
chromatography
• Detection
limit: not specified
Yes 0%
Li 2009 Not reported No Not reported N/A N/A
Pomier-Layrargues
1994
3 days Yes • Blood
• Abbott TDx
immunoassay
• Detection
limit 12 ng/mL
Post-hoc analysis
• Gas
chromatography-
mass spectroscopy
• Detection
limit: 1 ng/mL
No 19%
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Table 5. Baseline screening for benzodiazepines in trial participants (Continued)
Van der Rijt 1995 Recent Yes • Blood
• High-pressure
liquid
chromatography
• Detection
limit: not specified
Yes 0%
Zhu 1998 7 days No Not reported Not reported Not reported
Table 6. Serious adverse events
Trial Number of participants Included in analyses of
serious adverse events
Data included in pri-
mary analysis
Serious adverse events
Amodio 1997 13 No Cross-over RCT. Data
from the first treatment
period not described
Publication does not de-
scribe
any deaths or other seri-
ous adverse events
Barbaro 1998 527 Yes Cross-over RCT. Data
from the first treatment
period included
Thirteen non-re-
sponders in the flumaze-
nil group and 17 non re-
sponders in the placebo
group died 3 to 4 days
(range 2-6) after ran-
domisation. The causes
of dead were septic shock
(20 participants); hypo-
volaemic shock (8 par-
ticipants) and lactic aci-
dosis (2 participants) but
informationwas not pro-
vided on the number of
deaths by cause in each
group
Cadranel 1995 14 Yes Cross-over RCT. Data
from the first treatment
period included
One of 12 responders
died from septic shock
on day 4 and 2 of
6 non-responders died
from septic shock (day 2)
and lactic acidosis (day
4) but information is not
provided on the groups
to which they a were al-
located
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Table 6. Serious adverse events (Continued)
Dursun 2003 40 Yes Parallel-arm RCT. We
included all participants
in the analyses
Pub-
lication did not describe
any deaths or other seri-
ous adverse events
Giger-Mateeva 1999 10 No Cross-over RCT. Data
from the first treatment
period not described
Pub-
lication did not describe
any deaths or other seri-
ous adverse events
Gooday 1995 10 Yes Cross-over RCT. Data
from the first treatment
period included
Pub-
lication did not describe
any deaths or other seri-
ous adverse events
Gyr 1996 49 Yes Parallel-arm RCT. We
included all participants
in the analyses
Four of 28 participants
allocated to flumazenil
and 5 of 21 allocated
to placebo died within
4 weeks of the trial.
One participant in the
placebo group died with
respiratory failure dur-
ing the course of the
study. The authors de-
scribed participants as
having severe liver dis-
ease suggesting that the
cause of death in the re-
maining 8 participants
may have been cirrho-
sis-related although this
is not specifically stated.
The investigators classi-
fied the remaining ad-
verse events viz flushing,
nausea, vomiting, and ir-
ritability, which were ex-
perienced by 4 partici-
pants, as non-serious
Hermant 1991 12 Yes Parallel-arm RCT. We
included all participants
in the analyses
Pub-
lication did not describe
any deaths or other seri-
ous adverse events
Klotz 1989 2 No Cross-over RCT. Data
from the first treatment
period were not de-
Publication does not de-
scribe
any deaths or other seri-
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Table 6. Serious adverse events (Continued)
scribed ous adverse events
Lacetti 2000 54 Yes Parallel-arm RCT. We
include all participants
in the analyses
Six of 28 participants in
the flumazenil group and
5 of 26 in the control
group died. The causes
of death were not pro-
vided
Li 2009 72 Yes Par-
allel-arm RCT. The in-
cluded participants had
hepatic encephalopathy
associated with cirrho-
sis or acute liver fail-
ure. Data were not pro-
vide separately for the 2
groups
Five of 39 participants in
the flumazenil group and
4 of 33 participants in
the control group died.
The causes of death were
not provided
Pomier-Layrargues 1994 21 Yes Cross-over RCT. Data
from the first treatment
period were included
Pub-
lication did not describe
any deaths or other seri-
ous adverse events
Van der Rijt 1995 18 Yes Cross-over RCT. The in-
cluded participants had
hepatic encephalopathy
associated with cirrho-
sis or acute liver fail-
ure. Data were not pro-
vide separately for the
2 groups.Data from the
first treatment period
were included
Pub-
lication did not describe
any deaths or other seri-
ous adverse events. Two
participants with fulmi-
nant hepatic failure un-
derwent orthotopic liver
transplantation on day
one of the study
Zhu 1998 25 Yes Parallel-arm RCT. We
included all participants
in the analyses
Three of 13 participants
in the flumazenil group
and 5 of 12 participants
in the control group
died. The causes of death
were not provided
RCT: randomised clinical trial.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
Cochrane Hepato-Biliary Group Con-
trolled Trials Register
May 2017. (((benzodiazepine receptor OR GABA) AND (antagonist* OR
blocking agent*)) OR flumazenil OR flumazepil)
Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Li-
brary
2017, Issue 2. #1 MeSH descriptor: [GABA Antagonists] explode all trees
#2 MeSH descriptor: [Flumazenil] explode all trees
#3 ((benzodiazepine receptor or GABA) and (antagonist* or
blocking agent*)) or flumaze*il
#4 #1 or #2 or #3
#5 MeSH descriptor: [Liver Cirrhosis] explode all trees
#6 MeSH descriptor: [Hepatic Encephalopathy] explode all trees
#7 liver cirrhosis or hepatic encephalopathy
#8 #5 or #6 or #7
#9 #4 and #8
MEDLINE Ovid 1946 to May 2017. 1. exp GABA Antagonists/
2. exp Flumazenil/
3. (((benzodiazepine receptor or GABA) and (antagonist* or
blocking agent*)) or flumaze*il).mp. [mp=protocol supplemen-
tary concept, rare disease supplementary concept, title, original
title, abstract, name of substance word, subject heading word,
unique identifier]
4. 1 or 2 or 3
5. exp Liver Cirrhosis/
6. exp Hepatic Encephalopathy/
7. (liver cirrhosis or hepatic encephalopathy).mp. [mp=protocol
supplementary concept, rare disease supplementary concept, title,
original title, abstract, name of substance word, subject heading
word, unique identifier]
8. 5 or 6 or 7
9. 4 and 8
10. (random* or blind* or placebo* or meta-analysis).mp. [mp=
protocol supplementary concept, rare disease supplementary con-
cept, title, original title, abstract, name of substance word, subject
heading word, unique identifier]
11. 9 and 10
Embase Ovid 1974 to May 2017. 1. exp benzodiazepine receptor blocking agent/
2. exp 4 aminobutyric acid receptor blocking agent/
3. exp FLUMAZENIL/
4. (((benzodiazepine receptor or GABA) and (antagonist* or
blocking agent*)) or flumaze*il).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer]
5. 1 or 2 or 3 or 4
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(Continued)
6. exp liver cirrhosis/
7. exp hepatic encephalopathy/
8. (liver cirrhosis or hepatic encephalopathy).mp. [mp=title, ab-
stract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer]
9. 6 or 7 or 8
10. 5 and 9
11. (random* or blind* or placebo* or meta-analysis).mp. [mp=
title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer]
12. 10 and 11
Science Citation Index Expanded (Web of
Science)
1900 to May 2017. #5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-analysis)
#3 #2 AND #1
#2 TS=(liver cirrhosis or hepatic encephalopathy)
#1 TS=(((benzodiazepine receptor or GABA) and (antagonist* or
blocking agent*)) or flumaze*il)
LILACS (Bireme) 1982 to May 2017. (benzodiazepine receptor or GABA) and (antagonist$ or block-
ing agent$)) or flumaze$ [Words] and hepatic encephalopath$
[Words]
WH A T ’ S N E W
Last assessed as up-to-date: 5 May 2017.
Date Event Description
4 May 2017 New search has been performed Searches updated.
14 October 2016 New search has been performed The review methods and analyses are revised based on
the recent recommendations of the Cochrane Hep-
ato-Biliary Group, the MECIR guidelines, and the
Cochrane Handbook for Reviews of Interventions
14 October 2016 New search has been performed Title change. Previously, the review was published with
the title “Benzodiazepine receptor antagonists for hep-
atic encephalopathy”
9 May 2016 New citation required but conclusions have not
changed
We included two additional randomised clinical trials
(RCTs) in the analyses of benefits and harms and ex-
cluded one RCT from the analyses of benefits. The lat-
ter RCT and two additional observational studies are
included in analyses of harms
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review has been extensively revised compared to the original protocol and the previously published version of this current review
(Als-Nielsen 2004). The changes mainly reflect the current recommendations (Gluud 2017).
In the previous review (Als-Nielsen 2004), the primary outcomes included ’recovery’ from hepatic encephalopathy defined as complete
resolution of symptoms and ’improvement’ of hepatic encephalopathy. We removed outcome ’recovery.’ The term may be misleading
as episodes may recur. Furthermore, people may show some degree of impairment between episodes (Bajaj 2010). Based on current
guidelines (Gluud 2017), we assessed ’improvement’ as number of participants ’without improvement of hepatic encephalopathy.’ We
now include all-cause mortality as a primary outcome rather than ’survival.’
The previous version of the review included data from both periods of cross-over trials. In this review, we only included data from the
first treatment period because hepatic encephalopathy is fluctuating condition and because participants may die early in the randomised
clinical trials.
We now report the results of meta-analyses using risk ratios, instead of risk differences, and include observational studies to improve
our assessment of serious adverse events, Trial Sequential Analyses, and regression analysis (Harbord test) to evaluate the risk of small-
study effects. The bias assessment is also updated.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Antidotes [∗therapeutic use]; Chronic Disease; Flumazenil [∗therapeutic use]; GABA Modulators [∗therapeutic use];
GABA-A Receptor Antagonists; Hepatic Encephalopathy [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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